Aneurysm-Osteoarthritis Syndrome

Mendelian MONDO:0013426 Pathograph 33 Show in embeddings browser

Aneurysm-osteoarthritis syndrome (AOS), also classified as Loeys-Dietz syndrome type 3 (LDS3; formerly Loeys-Dietz syndrome type 1C), is an autosomal dominant connective tissue disorder caused by heterozygous pathogenic variants in SMAD3, an intracellular mediator of the transforming growth factor beta (TGF-beta) signaling pathway. It is characterized by the combination of arterial aneurysms, dissections, and tortuosity throughout the arterial tree together with a distinctive, early-onset osteoarthritis with osteochondritis dissecans that sets it apart from other heritable thoracic aortic disease (HTAD) syndromes. Additional features include mild craniofacial anomalies (hypertelorism, bifid uvula/cleft palate), skeletal manifestations (pectus deformity, scoliosis, arachnodactyly, pes planus, joint laxity), mitral valve abnormalities, and cutaneous findings. As in other Loeys-Dietz subtypes, aortic dissection can occur at smaller aortic diameters and younger ages than in Marfan syndrome, so early diagnosis, arterial-tree surveillance, medical therapy, and prophylactic surgery are central to management.

Ask OpenScientist

Ask a research question about Aneurysm-Osteoarthritis Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
1
Inheritance
8
Pathophys.
2
Histopath.
21
Phenotypes
1
Gaps
33
Pathograph
1
Genes
5
Medical Actions
5
Differentials
1
Models
1
References
1
Deep Research
🏷

Classifications

Harrison's Part
CARDIOVASCULAR GENETICS ENVIRONMENT DISEASE IMMUNE RHEUMATOLOGIC
🔗

Mappings

MONDO
MONDO:0013426 aneurysm-osteoarthritis syndrome
skos:exactMatch MONDO
MONDO models aneurysm-osteoarthritis syndrome as a subtype of Loeys-Dietz syndrome (MONDO:0018954) with SMAD3 as the causal gene; synonyms include Loeys-Dietz syndrome type 3 (LDS3) and Loeys-Dietz syndrome type 1C.
📘

Definitions

1
Molecular and clinical diagnosis
The diagnosis is established clinically and/or by identification of a heterozygous pathogenic variant in a Loeys-Dietz gene; SMAD3 is the causal gene for aneurysm-osteoarthritis syndrome (LDS type 3).
DIAGNOSTIC_CRITERIA
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"The diagnosis of LDS is established in (1) a proband with characteristic clinical findings or (2) by the identification of a heterozygous pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2"
GeneReviews specifies the molecular and clinical basis for establishing the diagnosis, including SMAD3 among the causal genes.
👪

Inheritance

1
Autosomal dominant inheritance HP:0000006
Aneurysm-osteoarthritis syndrome is inherited in an autosomal dominant manner; as with other Loeys-Dietz subtypes, a substantial fraction of probands carry a de novo SMAD3 variant, while the remainder inherit the variant from an affected parent.
Autosomal dominant inheritance
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"Approximately 75% of probands diagnosed with LDS have the disorder as the result of a de novo pathogenic variant; approximately 25% of individuals diagnosed with LDS have an affected parent."
GeneReviews documents autosomal dominant inheritance of Loeys-Dietz syndrome (which includes SMAD3-related LDS3/aneurysm-osteoarthritis syndrome), with a high proportion of de novo variants.
?

Discussions and Knowledge Gaps

1
Does angiotensin receptor blockade benefit SMAD3-related aneurysm-osteoarthritis syndrome by inhibiting aortic TGF-beta signaling, or only by reducing hemodynamic wall stress - and is TGF-beta the right therapeutic target in AOS at all?
CONTROVERSY OPEN arb_tgfbeta_target_uncertainty
Attached to
pathophysiology#TGF-beta Signaling Dysregulation
The entry models an ARB -> "TGF-beta Signaling Dysregulation" INHIBITS edge, but that edge is not directly evidenced in AOS. The GeneReviews statement attached to the ARB treatment supports only reduction of hemodynamic stress, not TGF-beta inhibition. Two SMAD3 mouse studies point away from TGF-beta as the actionable target: PMID:27688095 concludes that immune suppression may be more beneficial than targeting TGF-beta signaling, and PMID:23782924 nominates macrophage depletion and iNOS antagonism instead. The paradoxical-TGF-beta-increase model is inherited from the aortopathy_tgfbeta_dysregulation module and from Marfan/losartan biology, so there is a real risk of importing a mechanism that has not been demonstrated for SMAD3 specifically. Resolving this matters clinically, since ARB therapy is a modeled treatment for this disease.
Both refuting studies are MODEL_ORGANISM evidence, so they constrain the mechanistic claim rather than the clinical practice of using ARBs in AOS. Retained rather than deleting the target_mechanisms edge so the open question stays visible; a curator may prefer to retarget the edge to the hemodynamic-stress node instead.
Show evidence (2 references)
PMID:27688095 REFUTE Model Organism
"instead of targeting TGF-β signaling, immune suppression may be more beneficial"
Argues against TGF-beta signaling as the therapeutic target in SMAD3 aortic disease, in tension with the modeled ARB -> TGF-beta edge.
PMID:23782924 REFUTE Model Organism
"Macrophage depletion and iNOS antagonism represent 2 promising approaches"
Nominates immune/iNOS-directed rather than TGF-beta-directed intervention for SMAD3-related aneurysm.
⚙

Pathophysiology

8
SMAD3 Loss-of-Function
Heterozygous pathogenic variants in SMAD3 disrupt the receptor-regulated SMAD that transduces TGF-beta signals from activated TGF-beta receptors to the nucleus. SMAD3 forms a complex with the co-SMAD SMAD4 and regulates transcription of TGF-beta target genes. Loss of normal SMAD3 function is the conserved genetic trigger for the syndrome.
SMAD3 hgnc:6769 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves SMAD3 (hgnc:6769). hgnc:6769 is a gene from the HUGO Gene Nomenclature Committee.
SMAD protein signal transduction GO:0060395 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal SMAD protein signal transduction (GO:0060395). GO:0060395 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Experimental models
Patient-Derived SMAD3 Fibroblast and Vascular Smooth Muscle Cell Cultures PRIMARY CELL CULTURE Compares functional consequences of dominant-negative and haploinsufficient pathogenic SMAD3 variants.
Downstream
Reduced PRRX2-Dependent Aortic Microfibril Expression SMAD3 dysfunction reduces PRRX2 and the smooth-muscle-cell microfibril transcriptional program.
TGF-beta Signaling Dysregulation SMAD3 dysfunction paradoxically increases aortic TGF-beta pathway activity.
Cartilage TGF-beta Dysregulation and Early-Onset Osteoarthritis The same SMAD3 loss also disrupts TGF-beta-dependent cartilage homeostasis, driving the early-onset osteoarthritis arm.
Hypertelorism Hypertelorism is an observed pleiotropic manifestation of SMAD3-related LDS3; the intervening developmental mechanism is not resolved here.
Bifid Uvula or Cleft Palate Palatal/uvular abnormalities are observed pleiotropic manifestations of SMAD3-related LDS3; the intervening developmental mechanism is unresolved.
Scoliosis Scoliosis is an observed skeletal manifestation of SMAD3-related LDS3; the intervening tissue mechanism is not resolved here.
Pectus Deformity Pectus deformity is an observed skeletal manifestation of SMAD3-related LDS3; the intervening tissue mechanism is not resolved here.
Joint Laxity Joint laxity is an observed connective-tissue manifestation of SMAD3-related LDS3; the intervening tissue mechanism is not resolved here.
Arachnodactyly Arachnodactyly is an observed skeletal manifestation of SMAD3-related LDS3; the intervening developmental mechanism is not resolved here.
Pes Planus Pes planus is an observed skeletal manifestation of SMAD3-related LDS3; the intervening tissue mechanism is not resolved here.
Thin or Translucent Skin Thin/translucent skin is an observed connective-tissue manifestation of SMAD3-related LDS3; the intervening tissue mechanism is not resolved here.
Easy Bruising Easy bruising is an observed cutaneous manifestation of SMAD3-related LDS3; the intervening tissue mechanism is not resolved here.
Atrophic Scars Atrophic scarring is an observed cutaneous manifestation of SMAD3-related LDS3; the intervening tissue mechanism is not resolved here.
Reduced Bone Mineral Density Reduced bone mass is observed in SMAD3-related disease, but its causal path from SMAD3 dysfunction is not resolved here.
Atrial Fibrillation Atrial fibrillation is associated with SMAD3-related AOS, but the intervening mechanism independent of aortic disease remains unresolved.
Left Ventricular Hypertrophy Left ventricular hypertrophy is associated with SMAD3-related AOS, but the intervening mechanism remains unresolved.
Mitral Valve Prolapse Mitral valve disease is strongly associated with SMAD3-related LDS3, but the intervening valve-tissue mechanism is not resolved here.
Show evidence (1 reference)
PMID:21217753 SUPPORT Human Clinical
"the disease is caused by mutations in SMAD3. This gene encodes a member of the TGF-β pathway that is essential for TGF-β signal transmission"
van de Laar et al. identified SMAD3 as the causal gene, encoding an essential mediator of TGF-beta signal transmission.
Reduced PRRX2-Dependent Aortic Microfibril Expression
In a multigenerational SMAD3 p.Arg287Gln family, aortic smooth muscle cells showed reduced expression of microfibril genes and downregulation of PRRX2, a promoter-occupying regulator of five microfibril genes. SMAD3 overexpression rescued both PRRX2 and microfibril expression, defining a directly tested SMAD3-PRRX2-microfibril axis.
vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology.
SMAD3 hgnc:6769 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves SMAD3 (hgnc:6769). hgnc:6769 is a gene from the HUGO Gene Nomenclature Committee. PRRX2 hgnc:21338 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PRRX2 (hgnc:21338). hgnc:21338 is a gene from the HUGO Gene Nomenclature Committee.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Aortic Smooth-Muscle-to-Elastic-Lamella Disconnection Reduced microfibril production leaves elastic fibers poorly sheathed and separates smooth muscle cells from the lamellae.
Show evidence (2 references)
PMID:42273728 SUPPORT In Vitro
"RNA sequencing of Loeys-Dietz syndrome 3 SMCs revealed reduced microfibril gene expression."
Patient-derived aortic SMC transcriptomics directly supports reduced microfibril-gene expression.
PMID:42273728 SUPPORT In Vitro
"SMAD3 overexpression rescued both PRRX2 and microfibril expression."
Rescue by SMAD3 overexpression directly supports the direction of the SMAD3-PRRX2-microfibril regulatory relationship in patient-derived cells.
Aortic Smooth-Muscle-to-Elastic-Lamella Disconnection
Early human aortic pathology in SMAD3 variant carriers consists of smooth muscle cells separated from elastic lamellae by glycosaminoglycans and elastic fibers that are poorly decorated by multiple microfibril proteins, even while lamellar structure and SMC content remain relatively intact.
vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Aortic Medial Degeneration and Wall Weakening Loss of smooth-muscle-to-elastic-lamella coupling and microfibril support creates an early structural vulnerability that contributes to medial degeneration.
Show evidence (1 reference)
PMID:42273728 SUPPORT Human Clinical
"However, early pathology was evident, with SMCs separated from elastic lamellae by a thin layer of glycosaminoglycans. Confocal reconstructions revealed that elastic fibers were poorly decorated by microfibrils, with reduced fibrillin-1, fibrillin-2, microfibril associated glycoprotein-2,..."
Direct analysis of surgically obtained human aortas identifies an early tissue lesion preceding gross lamellar destruction.
TGF-beta Signaling Dysregulation
Despite SMAD3 being a positive transducer of TGF-beta signaling, SMAD3 mutations lead to paradoxically increased expression of key TGF-beta pathway components in the aortic wall, the same dysregulated-TGF-beta signature seen across the heritable thoracic aortic disease syndromes.
vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology.
transforming growth factor beta receptor signaling pathway GO:0007179 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased transforming growth factor beta receptor signaling pathway (GO:0007179). GO:0007179 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Aortic Medial Degeneration and Wall Weakening Dysregulated TGF-beta signaling drives maladaptive medial remodeling.
Show evidence (2 references)
PMID:21217753 SUPPORT Human Clinical
"SMAD3 mutations lead to increased aortic expression of several key players in the TGF-β pathway, including SMAD3"
Demonstrates paradoxically increased aortic TGF-beta pathway signaling, the conserved aortopathy mechanism.
PMID:27688095 SUPPORT Model Organism
"Although Smad3-/- aortas showed increased nuclear pSmad2 and pErk, indicating TGF-β receptor activation, downstream TGF-β-activated target genes were not upregulated."
Refines the TGF-beta paradox: in the Smad3-null model, receptor-proximal signaling (pSmad2, pErk) is increased while downstream SMAD3-dependent target-gene transcription fails.
Aortic Medial Degeneration and Wall Weakening
Dysregulated TGF-beta signaling together with the underlying connective tissue defect produces medial degeneration of the aortic wall. In the Smad3-null model the dominant findings are medial elastin (elastic fiber) disruption and adventitial inflammation with matrix metalloproteinase activation concentrated in inflammatory areas, progressively weakening the wall; this inflammatory, MMP-driven route is a notable AOS-specific feature.
vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology. macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Experimental models
Patient-Derived SMAD3 Fibroblast and Vascular Smooth Muscle Cell Cultures PRIMARY CELL CULTURE Measures vascular smooth-muscle differentiation and extracellular-matrix outputs relevant to aortic wall homeostasis.
Downstream
Progressive Arterial Aneurysm and Tortuosity Wall weakening permits progressive dilation and tortuosity.
Show evidence (3 references)
PMID:21217753 SUPPORT Human Clinical
"We delineated a new syndrome presenting with aneurysms, dissections and tortuosity throughout the arterial tree"
Establishes the systemic arterial-wall pathology (aneurysm, dissection, tortuosity) that reflects medial wall weakening.
PMID:27688095 SUPPORT Model Organism
"Aortic wall immunohistochemistry showed no increase in extracellular matrix and collagen accumulation, nor loss of vascular smooth muscle cells (VSMCs) but instead revealed medial elastin disruption and adventitial inflammation."
Identifies medial elastin disruption and adventitial inflammation (rather than SMC loss or ECM accumulation) as the medial-degeneration mechanism in the Smad3-null aorta.
PMID:23782924 SUPPORT Model Organism
"the underlying mechanism involved aberrant upregulation of inducible nitric oxide synthase (iNOS)-derived nitric oxide production and activation of elastolytic matrix metalloproteinases 2 and 9"
Shows macrophage iNOS-derived nitric oxide and elastolytic MMP2/9 activation as the mechanism of wall weakening in SMAD3-deficient aortas.
Progressive Arterial Aneurysm and Tortuosity
Progressive weakening of the arterial wall produces aneurysms and marked tortuosity that, unlike Marfan syndrome, are distributed widely throughout the arterial tree rather than confined to the aortic root.
transforming growth factor beta receptor signaling pathway GO:0007179 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased transforming growth factor beta receptor signaling pathway (GO:0007179). GO:0007179 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Aortic Dissection and Rupture Aneurysmal, weakened arteries are prone to dissection and rupture.
Thoracic Aortic Aneurysm Progressive aortic wall weakening produces thoracic, usually root, aneurysm.
Arterial Tortuosity Diffuse arteriopathy produces tortuosity throughout the arterial tree.
Cerebral (Intracranial) Aneurysm The generalized arteriopathy includes intracranial arteries.
Visceral and Iliac Artery Aneurysm The generalized arteriopathy includes visceral and iliac arteries.
Show evidence (1 reference)
PMID:21217753 SUPPORT Human Clinical
"aneurysms, dissections and tortuosity throughout the arterial tree"
Documents the widespread arterial aneurysm and tortuosity phenotype.
Aortic Dissection and Rupture
The weakened, aneurysmal arterial wall is prone to dissection and rupture. A clinically critical feature shared with other Loeys-Dietz subtypes is that dissection can occur at smaller aortic diameters and at younger ages than in Marfan syndrome, and vascular disease is not limited to the aortic root.
vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology.
Downstream
Aortic Dissection This clinical phenotype is the direct manifestation of the modeled dissection event.
Show evidence (4 references)
PMID:20301312 SUPPORT Human Clinical
"aortic dissection can occur at smaller aortic diameters and at younger ages than observed in Marfan syndrome; vascular disease is not limited to the aortic root"
GeneReviews documents the high dissection risk at small diameters and the diffuse arterial involvement characteristic of Loeys-Dietz syndrome.
PMID:22167769 SUPPORT Human Clinical
"Of the patients who first presented with joint abnormalities, 20% died suddenly from aortic dissection."
Quantifies the lethal risk of aortic dissection in AOS, including in patients who initially presented with joint disease.
PMID:30661052 SUPPORT Human Clinical
"Aortic events were documented in 37% of cases, with dissections accounting for 70% of events."
In an international SMAD3 cohort, aortic events (dissection or aneurysm repair) affected a substantial minority, most being dissections.
+ 1 more reference
Cartilage TGF-beta Dysregulation and Early-Onset Osteoarthritis
A hallmark that distinguishes aneurysm-osteoarthritis syndrome from other aneurysm syndromes is prominent early-onset osteoarthritis, frequently with osteochondritis dissecans. SMAD3 is essential for TGF-beta-mediated regulation of chondrocyte differentiation and cartilage homeostasis, so its disruption promotes cartilage degeneration.
chondrocyte CL:0000138 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves chondrocyte (CL:0000138). CL:0000138 is a cell type from the Cell Ontology.
regulation of chondrocyte differentiation GO:0032330 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal regulation of chondrocyte differentiation (GO:0032330). GO:0032330 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Early-Onset Osteoarthritis Cartilage dysregulation manifests as premature osteoarthritis.
Osteochondritis Dissecans Osteochondritis dissecans is part of the characteristic early joint-disease spectrum accompanying cartilage dysregulation.
Show evidence (1 reference)
PMID:21217753 SUPPORT Human Clinical
"In contrast with other aneurysm syndromes, most of these affected individuals presented with early-onset osteoarthritis"
Establishes early-onset osteoarthritis as the distinctive musculoskeletal feature of the syndrome.
✶

Histopathology

2
Aortic Medial Degeneration
Histology of human AOS aortic wall fragments shows disorganization of the tunica media with characteristic mucoid medial degeneration and accumulation of collagen in the media. This is the human tissue-level counterpart of the "Aortic Medial Degeneration and Wall Weakening" pathophysiology node.
Show evidence (1 reference)
PMID:22975338 SUPPORT Human Clinical
"On histology of aortic wall fragments, evident disorganization of the tunica media with fragmentation and loss of elastic fibers was observed, as well as characteristic mucoid medial degeneration and accumulation of collagen in media."
Direct human aortic histology documenting mucoid medial degeneration and medial collagen accumulation in AOS.
Aortic Elastic Fiber Fragmentation and Loss
Fragmentation and loss of medial elastic fibers accompanies the medial disorganization in AOS aortic wall specimens.
Show evidence (1 reference)
PMID:22975338 SUPPORT Human Clinical
"On histology of aortic wall fragments, evident disorganization of the tunica media with fragmentation and loss of elastic fibers was observed"
Human aortic histology documents elastic fiber fragmentation and loss.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Aneurysm-Osteoarthritis Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

21
Blood 1
Easy Bruising Bruising susceptibility HP:0000978 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bruising susceptibility (HP:0000978). HP:0000978 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"cutaneous findings (velvety and translucent skin, easy bruising, and dystrophic scars)"
GeneReviews explicitly lists easy bruising among LDS cutaneous findings.
Cardiovascular 7
Thoracic Aortic Aneurysm FREQUENT Aortic root aneurysm HP:0002616 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic root aneurysm (HP:0002616). HP:0002616 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:21217753 SUPPORT Human Clinical
"Thoracic aortic aneurysms and dissections are a main feature of connective tissue disorders"
Thoracic aortic aneurysm is a defining vascular feature of the syndrome.
PMID:22633655 SUPPORT Human Clinical
"In 71%, an aortic root aneurysm was found."
In a cohort of 44 AOS patients, aortic root aneurysm was present in 71%, supporting a frequent occurrence.
Aortic Dissection HP:0002647 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic dissection (HP:0002647). HP:0002647 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"aortic dissection can occur at smaller aortic diameters and at younger ages than observed in Marfan syndrome"
Documents aortic dissection and its occurrence at small diameters.
Arterial Tortuosity FREQUENT HP:0005116 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arterial tortuosity (HP:0005116). HP:0005116 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:21217753 SUPPORT Human Clinical
"aneurysms, dissections and tortuosity throughout the arterial tree"
Arterial tortuosity throughout the arterial tree is a hallmark feature.
PMID:22633655 SUPPORT Human Clinical
"and in 48%, arterial tortuosity was diagnosed"
Arterial tortuosity was diagnosed in 48% of the AOS cohort.
Cerebral (Intracranial) Aneurysm Cerebral berry aneurysm HP:0007029 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral berry aneurysm (HP:0007029). HP:0007029 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:20301312 SUPPORT Human Clinical
"vascular findings (cerebral, thoracic, and abdominal arterial aneurysms and/or dissections)"
GeneReviews documents cerebral arterial aneurysms as part of the LDS vascular spectrum.
PMID:22167769 SUPPORT Human Clinical
"Aneurysms and tortuosity were found in the aorta and other arteries throughout the body, including intracranial arteries."
AOS-specific cohort documents intracranial arterial aneurysms as part of the widespread arterial involvement.
PMID:22633655 SUPPORT Human Clinical
"cerebrovascular abnormalities were detected in 56% of"
In AOS patients undergoing cerebrovascular imaging, abnormalities were detected in the majority (56%), supporting frequent cerebrovascular involvement.
Atrial Fibrillation OCCASIONAL HP:0005110 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atrial fibrillation (HP:0005110). HP:0005110 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22633655 SUPPORT Human Clinical
"cardiac abnormalities were diagnosed, such as congenital heart defects (6%), mitral valve abnormalities (51%), left ventricular hypertrophy (19%), and atrial fibrillation (22%)."
In the 44-patient AOS cohort, atrial fibrillation was present in 22%, which falls in the HPO OCCASIONAL band (5-29%).
Left Ventricular Hypertrophy OCCASIONAL HP:0001712 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Left ventricular hypertrophy (HP:0001712). HP:0001712 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22633655 SUPPORT Human Clinical
"cardiac abnormalities were diagnosed, such as congenital heart defects (6%), mitral valve abnormalities (51%), left ventricular hypertrophy (19%), and atrial fibrillation (22%)."
In the 44-patient AOS cohort, left ventricular hypertrophy was present in 19%, which falls in the HPO OCCASIONAL band (5-29%).
Mitral Valve Prolapse FREQUENT HP:0001634 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mitral valve prolapse (HP:0001634). HP:0001634 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:35662564 SUPPORT Other
"LDS Type 3 demonstrated an increased prevalence of mitral valve prolapse and arthritis"
A systematic review reports increased mitral valve prolapse (and arthritis) specifically in SMAD3-related LDS type 3.
PMID:22633655 SUPPORT Human Clinical
"mitral valve abnormalities (51%)"
Mitral valve abnormalities were present in 51% of the AOS cohort.
PMID:38508323 SUPPORT Human Clinical
"There was significant intrafamilial phenotypic variability within the cohort with the predominant cardiovascular abnormality being mitral valve disease followed by aortic disease."
An independently ascertained 2024 family cohort confirms that mitral valve disease can predominate and emphasizes intrafamilial variability.
Eye 1
Hypertelorism HP:0000316 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertelorism (HP:0000316). HP:0000316 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"craniofacial features (hypertelorism, strabismus, bifid uvula / cleft palate, and craniosynostosis that can involve any sutures)"
GeneReviews lists hypertelorism among the craniofacial features of LDS.
Head and Neck 1
Bifid Uvula or Cleft Palate HP:0000193 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bifid uvula (HP:0000193). HP:0000193 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"bifid uvula / cleft palate"
Bifid uvula/cleft palate is a recognized craniofacial feature.
Integument 2
Thin or Translucent Skin Thin skin HP:0000963 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thin skin (HP:0000963). HP:0000963 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"cutaneous findings (velvety and translucent skin, easy bruising, and dystrophic scars)"
GeneReviews documents thin/translucent skin, easy bruising, and dystrophic scars among the cutaneous features of Loeys-Dietz syndrome.
Atrophic Scars HP:0001075 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atrophic scars (HP:0001075). HP:0001075 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"cutaneous findings (velvety and translucent skin, easy bruising, and dystrophic scars)"
GeneReviews explicitly lists dystrophic scarring among LDS cutaneous findings.
Limbs 2
Arachnodactyly HP:0001166 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arachnodactyly (HP:0001166). HP:0001166 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"Loeys-Dietz syndrome (LDS) is characterized by vascular findings (cerebral, thoracic, and abdominal arterial aneurysms and/or dissections), skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis, joint laxity, arachnodactyly, talipes equinovarus, and cervical spine malformation..."
GeneReviews lists arachnodactyly among LDS skeletal manifestations.
Pes Planus HP:0001763 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pes planus (HP:0001763). HP:0001763 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"Assess for skeletal deformity, joint manifestations, pes planus, hernia, and allergic and inflammatory manifestations at each visit or as needed."
GeneReviews explicitly includes pes planus in LDS surveillance.
Musculoskeletal 5
Early-Onset Osteoarthritis FREQUENT HP:0002758 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoarthritis (HP:0002758), qualified as juvenile onset. HP:0002758 is a phenotype from the Human Phenotype Ontology.
Onset: JUVENILE
Show evidence (2 references)
PMID:21217753 SUPPORT Human Clinical
"In contrast with other aneurysm syndromes, most of these affected individuals presented with early-onset osteoarthritis"
Early-onset osteoarthritis is the distinguishing feature of the syndrome.
PMID:22167769 SUPPORT Human Clinical
"In the majority of patients, early-onset joint abnormalities, including osteoarthritis and osteochondritis dissecans, were the initial symptom for which medical advice was sought."
In the AOS phenotypic-spectrum cohort, early-onset osteoarthritis was the presenting feature in the majority of patients, supporting a very frequent occurrence.
Scoliosis HP:0002650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scoliosis (HP:0002650). HP:0002650 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis, joint laxity, arachnodactyly, talipes equinovarus, and cervical spine malformation and/or instability)"
Scoliosis is listed among the skeletal manifestations of LDS.
Pectus Deformity Pectus excavatum HP:0000767 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pectus excavatum (HP:0000767). HP:0000767 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"skeletal manifestations (pectus excavatum or pectus carinatum"
Pectus deformity is a documented skeletal feature.
Joint Laxity Joint hypermobility HP:0001382 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint hypermobility (HP:0001382). HP:0001382 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"Loeys-Dietz syndrome (LDS) is characterized by vascular findings (cerebral, thoracic, and abdominal arterial aneurysms and/or dissections), skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis, joint laxity, arachnodactyly, talipes equinovarus, and cervical spine malformation..."
Joint laxity is listed among the skeletal manifestations of LDS.
Reduced Bone Mineral Density HP:0004349 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced bone mineral density (HP:0004349). HP:0004349 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32154675 SUPPORT Human Clinical
"Our data underline the high prevalence of decreased bone mass in SRD and more generally in TGFβvs (Kirmani et al., 2010) that can become an important issue in patients care."
A SMAD3 cohort/review reports a high prevalence of reduced bone mass; frequency is omitted because the quoted sentence does not provide a band.
Other 2
Visceral and Iliac Artery Aneurysm FREQUENT HP:4000067 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Iliac artery aneurysm (HP:4000067). HP:4000067 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:22633655 SUPPORT Human Clinical
"In 33%, aneurysms in other arteries in the thorax and abdomen were diagnosed"
One third of the AOS cohort had aneurysms in arteries beyond the aortic root, in the thorax and abdomen.
PMID:22975338 SUPPORT Human Clinical
"The common iliac artery was most commonly affected (37%), followed by the superior mesenteric artery (15%), celiac trunk (11%), and splenic artery (9%)."
Quantifies the distribution of visceral and iliac artery aneurysms in AOS, with the common iliac artery most affected.
Osteochondritis Dissecans HP:0010886 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteochondritis dissecans (HP:0010886). HP:0010886 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22167769 SUPPORT Human Clinical
"In the majority of patients, early-onset joint abnormalities, including osteoarthritis and osteochondritis dissecans, were the initial symptom for which medical advice was sought."
Osteochondritis dissecans is explicitly reported among the early-onset joint abnormalities of AOS.
🧬

Genetic Associations

1
SMAD3 (Causative)
Gene: SMAD3 hgnc:6769 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SMAD3 (hgnc:6769). hgnc:6769 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (4 references)
PMID:21217753 SUPPORT Human Clinical
"We mapped the genetic locus to chromosome 15q22.2-24.2 and show that the disease is caused by mutations in SMAD3"
Identifies SMAD3 (15q22) as the causal gene for the syndrome.
PMID:30661052 SUPPORT Human Clinical
"SMAD3 pathogenic variants cause thoracic aortic aneurysms and dissections in the majority of individuals with variable age of onset and reduced penetrance."
Documents autosomal dominant SMAD3-driven aortic disease with variable onset and reduced penetrance.
PMID:30661052 SUPPORT Human Clinical
"The median age at first aortic event was significantly lower in individuals with SMAD3 MH2 missense variants than those with HI variants"
Genotype-phenotype correlation: MH2-domain missense variants are associated with earlier aortic events than haploinsufficiency variants.
+ 1 more reference
💊

Medical Actions

5
Angiotensin Receptor Blocker Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: losartan CHEBI:6541 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses losartan (CHEBI:6541). CHEBI:6541 is a therapeutic agent from Chemical Entities of Biological Interest.
Angiotensin receptor blockers (e.g., losartan) are used to reduce hemodynamic stress and are hypothesized to attenuate dysregulated TGF-beta signaling in the aortic wall.
Mechanism Target:
INHIBITS TGF-beta Signaling Dysregulation — Angiotensin receptor blockade (losartan) is proposed to attenuate the dysregulated aortic TGF-beta signaling that drives medial degeneration, in addition to lowering hemodynamic wall stress. IMPORTANT: this edge is a mechanistic hypothesis, not an evidenced effect in AOS. The attached GeneReviews evidence supports only the hemodynamic-stress rationale, and the SMAD3 mouse literature argues against TGF-beta as the actionable target. See discussion `arb_tgfbeta_target_uncertainty`.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"angiotensin receptor blockers, beta-adrenergic receptor blockers, or other medications are used to reduce hemodynamic stress"
GeneReviews documents angiotensin receptor blockers to reduce hemodynamic stress in LDS.
Beta-Adrenergic Blocker Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: beta-adrenergic antagonist NCIT:C29576 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses beta-adrenergic antagonist (NCIT:C29576). NCIT:C29576 is a therapeutic agent from the NCI Thesaurus.
Beta-adrenergic receptor blockers reduce hemodynamic stress on the aortic wall to slow aneurysm progression.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"angiotensin receptor blockers, beta-adrenergic receptor blockers, or other medications are used to reduce hemodynamic stress"
GeneReviews documents beta-adrenergic receptor blockers to reduce hemodynamic stress in LDS.
Prophylactic Aortic and Arterial Surgery
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Aneurysms are amenable to early and aggressive surgical intervention; prophylactic repair at appropriate thresholds prevents dissection and rupture.
Show evidence (2 references)
PMID:20301312 SUPPORT Human Clinical
"aneurysms are amenable to early and aggressive surgical intervention"
GeneReviews documents early, aggressive surgical repair of aneurysms in LDS.
PMID:22633655 SUPPORT Human Clinical
"Dissections can occur at relatively mildly increased aortic diameters; therefore, early elective repair of the ascending aorta should be considered."
Because dissection occurs at mildly increased diameters in AOS, early elective ascending-aorta repair is recommended.
Avoidance of Contact, Competitive, and Isometric Exercise
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Patients should avoid contact and competitive sports and isometric exercise because these activities can impose abrupt hemodynamic stress on a fragile arterial wall.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"Contact sports, competitive sports, and isometric exercise"
GeneReviews lists contact/competitive sports and isometric exercise among the agents/circumstances to avoid in Loeys-Dietz syndrome.
Pregnancy and Peripartum Aortic Surveillance
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Pregnancy and the postpartum period are high-risk intervals in which aortic dissection/rupture and uterine rupture may occur, so aortic imaging is performed more frequently during gestation and in the weeks after delivery, and medical therapy is reviewed for fetal safety.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"Pregnancy and the postpartum period can be dangerous for women with LDS because of increased risk of aortic dissection/rupture and uterine rupture. Increased frequency of aortic imaging is recommended, both during pregnancy and in the weeks following delivery."
GeneReviews documents the peripartum aortic-catastrophe and uterine-rupture risk in Loeys-Dietz syndrome and the intensified aortic imaging schedule it warrants.
🔬

Biochemical Markers

1
N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) (Elevated relative to matched controls)
Pathograph Readouts
Correlates With Aortic Medial Degeneration and Wall Weakening Positive Monitoring
Higher NT-proBNP tracks with higher aortic pulse wave velocity (increased aortic stiffness), making it a candidate circulating correlate of the degenerated, stiffened aortic wall. This is an observed correlation in a single cohort, not a validated surrogate endpoint.
Show evidence (1 reference)
PMID:22633655 SUPPORT Human Clinical
"Aortic pulse wave velocity was high-normal (9.2 ± 2.2 m/s), indicating increased aortic stiffness, which strongly correlated with NT-proBNP (r = 0.731, p = 0.005)."
Quantifies the correlation between NT-proBNP and aortic stiffness in the AOS cohort.
Show evidence (1 reference)
PMID:22633655 SUPPORT Human Clinical
"N-terminal brain natriuretic peptide (NT-proBNP) was significantly higher in AOS patients compared with matched controls (p < 0.001)."
Establishes NT-proBNP elevation in AOS relative to matched controls.
🔬

Diagnosis

2
Molecular confirmation of a pathogenic SMAD3 variant
Sequence analysis with deletion/duplication coverage, usually through a heritable thoracic aortic disease or connective-tissue multigene panel, identifies a heterozygous pathogenic or likely pathogenic SMAD3 variant. A variant of uncertain significance alone does not establish the diagnosis.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Results: A heterozygous pathogenic or likely pathogenic SMAD3 variant in a compatible clinical or family context establishes SMAD3-related LDS3/AOS.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"The diagnosis of LDS is established in (1) a proband with characteristic clinical findings or (2) by the identification of a heterozygous pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2"
GeneReviews directly supports molecular confirmation and includes SMAD3.
Baseline and serial whole-arterial-tree imaging
Echocardiography measures the aortic root and ascending aorta, while contrast CT angiography or MR angiography from head to pelvis identifies extra-aortic aneurysms, dissections, and arterial tortuosity that echocardiography cannot detect.
Diagnostic Imaging Testing NCIT:C16502 NCI Thesaurus (NCIT)
Results: Aortic-root/ascending-aortic dimensions and the presence, location, and growth of aneurysm, dissection, or tortuosity establish vascular extent and guide surveillance and prophylactic repair.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"Echocardiography to monitor the status of the aortic root and ascending aorta (at least annually) and magnetic resonance angiography or computerized tomography angiography to assess the entire arterial tree"
GeneReviews directly supports combined echocardiographic and complete arterial-tree imaging.
📈

Progression

2
Childhood and adolescence
Age: Childhood to early adulthood
Early-onset joint disease (osteoarthritis and osteochondritis dissecans) is frequently the first manifestation, often prompting the initial medical evaluation. Aortic events in childhood have not been observed in SMAD3 cohorts.
Show evidence (2 references)
PMID:22167769 SUPPORT Human Clinical
"In the majority of patients, early-onset joint abnormalities, including osteoarthritis and osteochondritis dissecans, were the initial symptom for which medical advice was sought."
Establishes joint disease as the typical presenting feature earlier in the disease course.
PMID:30661052 SUPPORT Human Clinical
"No aortic events in childhood were observed."
Supports the absence of aortic events during childhood, informing gene-specific surveillance.
Adulthood
Age: Adulthood
Aortic aneurysms and dissections accrue with age; the cumulative risk of an aortic event reaches 50% by age 54, and aortic dissection is a major cause of sudden death.
Show evidence (2 references)
PMID:30661052 SUPPORT Human Clinical
"The cumulative risk of an aortic event was 50% at 54 years of age."
Quantifies age-dependent cumulative aortic-event risk in the adult course.
PMID:22167769 SUPPORT Human Clinical
"Of the patients who first presented with joint abnormalities, 20% died suddenly from aortic dissection."
Documents sudden death from aortic dissection as a major adult outcome.
📊

Prevalence

1
Worldwide
Unknown Unknown
Aneurysm-osteoarthritis syndrome (SMAD3-related Loeys-Dietz syndrome type 3) is a rare disorder; a precise population prevalence has not been established. The only quantitative anchor available is the share of familial thoracic aortic aneurysm and dissection attributable to AOS (~2%), which is a disease-fraction rather than a population rate. The incidence of AOS among patients with primary visceral and iliac artery aneurysms is explicitly stated to be unknown.
Show evidence (1 reference)
PMID:22975338 SUPPORT Human Clinical
"AOS is estimated to be responsible for ~2% of familial thoracic aortic aneurysms and dissections"
Provides the only quantitative occurrence anchor for AOS: a ~2% share of familial thoracic aortic aneurysm and dissection. Population prevalence remains undetermined, so prevalence_class stays UNKNOWN.
🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Aneurysm-Osteoarthritis Syndrome:

Marfan syndrome MONDO:0007947
Overlapping Features Marfan syndrome overlaps in aortic-root aneurysm, skeletal findings, and autosomal dominant inheritance.
Distinguishing Features
  • FBN1-associated ectopia lentis favors Marfan syndrome.
  • The absence of characteristic early-onset osteoarthritis and osteochondritis dissecans favors Marfan syndrome.
  • AOS/LDS can dissect at smaller diameters and has more diffuse arterial involvement; SMAD3 molecular testing distinguishes AOS.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"aortic dissection can occur at smaller aortic diameters and at younger ages than observed in Marfan syndrome; vascular disease is not limited to the aortic root"
Directly states two vascular features distinguishing LDS from Marfan syndrome.
Vascular Ehlers-Danlos syndrome MONDO:0017314
Overlapping Features Vascular Ehlers-Danlos syndrome can also present with arterial aneurysm, dissection or rupture and translucent skin.
Distinguishing Features
  • COL3A1 molecular findings favor vascular EDS.
  • Characteristic tissue fragility and hollow-organ rupture favor vascular EDS.
  • SMAD3-related early osteoarthritis and osteochondritis dissecans favor AOS.
Other molecular subtypes of Loeys-Dietz syndrome MONDO:0018954
Overlapping Features TGFBR1-, TGFBR2-, TGFB2-, TGFB3-, SMAD2-, and IPO8-related LDS share the diffuse aortopathy and overlapping craniofacial, skeletal, and cutaneous findings.
Distinguishing Features
  • Identification of a pathogenic variant in SMAD3 establishes LDS3/AOS.
  • Prominent premature osteoarthritis is particularly characteristic of LDS3.
Show evidence (1 reference)
PMID:20301312 SUPPORT Human Clinical
"The diagnosis of LDS is established in (1) a proband with characteristic clinical findings or (2) by the identification of a heterozygous pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2"
Lists the molecular causes that must be separated within the overlapping dominant LDS spectrum.
Familial thoracic aortic aneurysm and dissection MONDO:0019625
Overlapping Features Nonsyndromic familial HTAD can present with an autosomal dominant thoracic aneurysm/dissection phenotype without obvious systemic features.
Distinguishing Features
  • A pathogenic SMAD3 variant with early osteoarthritis, osteochondritis dissecans, arterial tortuosity, and extra-aortic aneurysms supports syndromic AOS rather than an isolated familial TAAD presentation.
Multiple epiphyseal dysplasia MONDO:0016648
Overlapping Features Multiple epiphyseal dysplasia is an important musculoskeletal differential when premature generalized osteoarthritis is the presenting complaint.
Distinguishing Features
  • Epiphyseal dysplasia on skeletal imaging and a causal COMP, MATN3, COL9A1, COL9A2, or COL9A3 variant favor multiple epiphyseal dysplasia.
  • Diffuse aneurysm, dissection, or arterial tortuosity with a pathogenic SMAD3 variant establishes AOS.
🧫

Experimental Models

1
Patient-Derived SMAD3 Fibroblast and Vascular Smooth Muscle Cell Cultures PRIMARY_CELL_CULTURE
Primary fibroblasts and vascular smooth muscle cells from individuals with pathogenic/likely pathogenic SMAD3 variants were compared across dominant-negative MH2 and haploinsufficient variant classes. The system resolves variant-class effects on differentiation, smooth-muscle markers, MYH11 isoforms, and extracellular-matrix formation. It is limited by small numbers of patient lines, in-vitro differentiation, and the borderline clinical genotype-event comparisons; it does not reproduce arterial biomechanics, immune recruitment, or longitudinal aneurysm formation.
dominant-negative SMAD3 MH2-domain variants haploinsufficient SMAD3 variants control cell lines
vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology. fibroblast CL:0000057 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
Primary patient-derived dermal fibroblasts and vascular smooth muscle cells
Culture
Monolayer culture with fibroblast-to-myofibroblast differentiation
Publication
DOI:10.1093/hmg/ddae044
Pathograph links
SMAD3 Loss-of-Function Compares functional consequences of dominant-negative and haploinsufficient pathogenic SMAD3 variants.
Show evidence (1 reference)
DOI:10.1093/hmg/ddae044 SUPPORT Human Clinical
"Pathogenic (P)/likely pathogenic (LP) SMAD3 variants cause Loeys-Dietz syndrome type 3 (LDS3), which is characterized by arterial aneurysms, dissections and tortuosity throughout the vascular system combined with osteoarthritis."
Establishes pathogenic SMAD3 variants as the genetic cause represented by the primary-cell model.
Aortic Medial Degeneration and Wall Weakening Measures vascular smooth-muscle differentiation and extracellular-matrix outputs relevant to aortic wall homeostasis.
Show evidence (1 reference)
DOI:10.1093/hmg/ddae044 SUPPORT In Vitro
"DN SMAD3 variant myofibroblasts demonstrated reduced extracellular matrix formation compared to control cell lines."
Directly supports the model's extracellular-matrix readout relevant to medial wall integrity, without claiming that the culture reproduces the intact aorta.
Findings
Dominant-negative and haploinsufficient SMAD3 variants produced distinct differentiation, smooth-muscle-marker, MYH11-isoform, and matrix phenotypes.
"Fibroblasts carrying DN SMAD3 variants displayed reduced differentiation potential, contrasting with increased differentiation potential in HI SMAD3 variant fibroblasts."
Show evidence (1 reference)
DOI:10.1093/hmg/ddae044 SUPPORT In Vitro
"Fibroblasts carrying DN SMAD3 variants displayed reduced differentiation potential, contrasting with increased differentiation potential in HI SMAD3 variant fibroblasts."
Directly states the opposing differentiation phenotypes of the two pathogenic-variant classes.
Show evidence (1 reference)
DOI:10.1093/hmg/ddae044 SUPPORT In Vitro
"A retrospective analysis on clinical data from individuals with a P/LP SMAD3 variant and functional analyses on SMAD3 patient-derived VSMCs and SMAD3 patient-derived fibroblasts, differentiated into myofibroblasts."
Defines the patient-derived primary-cell systems and the fibroblast differentiation design.
{ }

Source YAML

click to show 
name: Aneurysm-Osteoarthritis Syndrome
creation_date: "2026-07-29T00:00:00Z"
category: Mendelian
description: >
  Aneurysm-osteoarthritis syndrome (AOS), also classified as Loeys-Dietz
  syndrome type 3 (LDS3; formerly Loeys-Dietz syndrome type 1C), is an
  autosomal dominant connective tissue disorder caused by heterozygous
  pathogenic variants in SMAD3, an intracellular mediator of the transforming
  growth factor beta (TGF-beta) signaling pathway. It is characterized by the
  combination of arterial aneurysms, dissections, and tortuosity throughout the
  arterial tree together with a distinctive, early-onset osteoarthritis with
  osteochondritis dissecans that sets it apart from other heritable thoracic
  aortic disease (HTAD) syndromes. Additional features include mild craniofacial
  anomalies (hypertelorism, bifid uvula/cleft palate), skeletal manifestations
  (pectus deformity, scoliosis, arachnodactyly, pes planus, joint laxity), mitral
  valve abnormalities, and cutaneous findings. As in other Loeys-Dietz subtypes,
  aortic dissection can occur at smaller aortic diameters and younger ages than in
  Marfan syndrome, so early diagnosis, arterial-tree surveillance, medical therapy,
  and prophylactic surgery are central to management.
disease_term:
  preferred_term: aneurysm-osteoarthritis syndrome
  term:
    id: MONDO:0013426
    label: aneurysm-osteoarthritis syndrome
classifications:
  harrisons_chapter:
  - classification_value: CARDIOVASCULAR
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  - classification_value: IMMUNE_RHEUMATOLOGIC
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0013426
      label: aneurysm-osteoarthritis syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO models aneurysm-osteoarthritis syndrome as a subtype of Loeys-Dietz
      syndrome (MONDO:0018954) with SMAD3 as the causal gene; synonyms include
      Loeys-Dietz syndrome type 3 (LDS3) and Loeys-Dietz syndrome type 1C.
definitions:
- name: Molecular and clinical diagnosis
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    The diagnosis is established clinically and/or by identification of a
    heterozygous pathogenic variant in a Loeys-Dietz gene; SMAD3 is the causal
    gene for aneurysm-osteoarthritis syndrome (LDS type 3).
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of LDS is established in (1) a proband with characteristic
      clinical findings or (2) by the identification of a heterozygous
      pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2
    explanation: >-
      GeneReviews specifies the molecular and clinical basis for establishing the
      diagnosis, including SMAD3 among the causal genes.
differential_diagnoses:
- name: Marfan syndrome
  description: >-
    Marfan syndrome overlaps in aortic-root aneurysm, skeletal findings, and
    autosomal dominant inheritance.
  distinguishing_features:
  - FBN1-associated ectopia lentis favors Marfan syndrome.
  - >-
    The absence of characteristic early-onset osteoarthritis and
    osteochondritis dissecans favors Marfan syndrome.
  - >-
    AOS/LDS can dissect at smaller diameters and has more diffuse arterial
    involvement; SMAD3 molecular testing distinguishes AOS.
  disease_term:
    preferred_term: Marfan syndrome
    term:
      id: MONDO:0007947
      label: Marfan syndrome
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aortic dissection can occur at smaller aortic diameters and at younger
      ages than observed in Marfan syndrome; vascular disease is not limited to
      the aortic root
    explanation: >-
      Directly states two vascular features distinguishing LDS from Marfan
      syndrome.
- name: Vascular Ehlers-Danlos syndrome
  description: >-
    Vascular Ehlers-Danlos syndrome can also present with arterial aneurysm,
    dissection or rupture and translucent skin.
  distinguishing_features:
  - COL3A1 molecular findings favor vascular EDS.
  - Characteristic tissue fragility and hollow-organ rupture favor vascular EDS.
  - >-
    SMAD3-related early osteoarthritis and osteochondritis dissecans favor AOS.
  disease_term:
    preferred_term: vascular Ehlers-Danlos syndrome
    term:
      id: MONDO:0017314
      label: Ehlers-Danlos syndrome, vascular type
- name: Other molecular subtypes of Loeys-Dietz syndrome
  description: >-
    TGFBR1-, TGFBR2-, TGFB2-, TGFB3-, SMAD2-, and IPO8-related LDS share the
    diffuse aortopathy and overlapping craniofacial, skeletal, and cutaneous
    findings.
  distinguishing_features:
  - Identification of a pathogenic variant in SMAD3 establishes LDS3/AOS.
  - Prominent premature osteoarthritis is particularly characteristic of LDS3.
  disease_term:
    preferred_term: Loeys-Dietz syndrome
    term:
      id: MONDO:0018954
      label: Loeys-Dietz syndrome
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of LDS is established in (1) a proband with characteristic
      clinical findings or (2) by the identification of a heterozygous
      pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2
    explanation: >-
      Lists the molecular causes that must be separated within the overlapping
      dominant LDS spectrum.
- name: Familial thoracic aortic aneurysm and dissection
  description: >-
    Nonsyndromic familial HTAD can present with an autosomal dominant thoracic
    aneurysm/dissection phenotype without obvious systemic features.
  distinguishing_features:
  - >-
    A pathogenic SMAD3 variant with early osteoarthritis, osteochondritis
    dissecans, arterial tortuosity, and extra-aortic aneurysms supports
    syndromic AOS rather than an isolated familial TAAD presentation.
  disease_term:
    preferred_term: familial thoracic aortic aneurysm and aortic dissection
    term:
      id: MONDO:0019625
      label: familial thoracic aortic aneurysm and aortic dissection
- name: Multiple epiphyseal dysplasia
  description: >-
    Multiple epiphyseal dysplasia is an important musculoskeletal differential
    when premature generalized osteoarthritis is the presenting complaint.
  distinguishing_features:
  - >-
    Epiphyseal dysplasia on skeletal imaging and a causal COMP, MATN3, COL9A1,
    COL9A2, or COL9A3 variant favor multiple epiphyseal dysplasia.
  - >-
    Diffuse aneurysm, dissection, or arterial tortuosity with a pathogenic SMAD3
    variant establishes AOS.
  disease_term:
    preferred_term: multiple epiphyseal dysplasia
    term:
      id: MONDO:0016648
      label: multiple epiphyseal dysplasia
references:
- reference: PMID:20301312
  title: "Loeys-Dietz Syndrome."
  tags:
  - GeneReviews
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Aneurysm-osteoarthritis syndrome is inherited in an autosomal dominant
    manner; as with other Loeys-Dietz subtypes, a substantial fraction of
    probands carry a de novo SMAD3 variant, while the remainder inherit the
    variant from an affected parent.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately 75% of probands diagnosed with LDS have the disorder as the
      result of a de novo pathogenic variant; approximately 25% of individuals
      diagnosed with LDS have an affected parent.
    explanation: >-
      GeneReviews documents autosomal dominant inheritance of Loeys-Dietz
      syndrome (which includes SMAD3-related LDS3/aneurysm-osteoarthritis
      syndrome), with a high proportion of de novo variants.
pathophysiology:
- name: SMAD3 Loss-of-Function
  biological_scale: MOLECULAR
  description: >-
    Heterozygous pathogenic variants in SMAD3 disrupt the receptor-regulated
    SMAD that transduces TGF-beta signals from activated TGF-beta receptors to
    the nucleus. SMAD3 forms a complex with the co-SMAD SMAD4 and regulates
    transcription of TGF-beta target genes. Loss of normal SMAD3 function is the
    conserved genetic trigger for the syndrome.
  biological_processes:
  - preferred_term: SMAD protein signal transduction
    term:
      id: GO:0060395
      label: SMAD protein signal transduction
    modifier: ABNORMAL
  genes:
  - preferred_term: SMAD3
    term:
      id: hgnc:6769
      label: SMAD3
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the disease is caused by mutations in SMAD3. This gene encodes a member
      of the TGF-β pathway that is essential for TGF-β signal transmission
    explanation: >-
      van de Laar et al. identified SMAD3 as the causal gene, encoding an
      essential mediator of TGF-beta signal transmission.
  downstream:
  - target: Reduced PRRX2-Dependent Aortic Microfibril Expression
    description: >-
      SMAD3 dysfunction reduces PRRX2 and the smooth-muscle-cell microfibril
      transcriptional program.
  - target: TGF-beta Signaling Dysregulation
    description: >-
      SMAD3 dysfunction paradoxically increases aortic TGF-beta pathway
      activity.
  - target: Cartilage TGF-beta Dysregulation and Early-Onset Osteoarthritis
    description: >-
      The same SMAD3 loss also disrupts TGF-beta-dependent cartilage
      homeostasis, driving the early-onset osteoarthritis arm.
  - target: Hypertelorism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Hypertelorism is an observed pleiotropic manifestation of SMAD3-related
      LDS3; the intervening developmental mechanism is not resolved here.
  - target: Bifid Uvula or Cleft Palate
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Palatal/uvular abnormalities are observed pleiotropic manifestations of
      SMAD3-related LDS3; the intervening developmental mechanism is unresolved.
  - target: Scoliosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Scoliosis is an observed skeletal manifestation of SMAD3-related LDS3;
      the intervening tissue mechanism is not resolved here.
  - target: Pectus Deformity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Pectus deformity is an observed skeletal manifestation of SMAD3-related
      LDS3; the intervening tissue mechanism is not resolved here.
  - target: Joint Laxity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Joint laxity is an observed connective-tissue manifestation of
      SMAD3-related LDS3; the intervening tissue mechanism is not resolved here.
  - target: Arachnodactyly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Arachnodactyly is an observed skeletal manifestation of SMAD3-related
      LDS3; the intervening developmental mechanism is not resolved here.
  - target: Pes Planus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Pes planus is an observed skeletal manifestation of SMAD3-related LDS3;
      the intervening tissue mechanism is not resolved here.
  - target: Thin or Translucent Skin
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Thin/translucent skin is an observed connective-tissue manifestation of
      SMAD3-related LDS3; the intervening tissue mechanism is not resolved here.
  - target: Easy Bruising
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Easy bruising is an observed cutaneous manifestation of SMAD3-related
      LDS3; the intervening tissue mechanism is not resolved here.
  - target: Atrophic Scars
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Atrophic scarring is an observed cutaneous manifestation of SMAD3-related
      LDS3; the intervening tissue mechanism is not resolved here.
  - target: Reduced Bone Mineral Density
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reduced bone mass is observed in SMAD3-related disease, but its causal
      path from SMAD3 dysfunction is not resolved here.
  - target: Atrial Fibrillation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Atrial fibrillation is associated with SMAD3-related AOS, but the
      intervening mechanism independent of aortic disease remains unresolved.
  - target: Left Ventricular Hypertrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Left ventricular hypertrophy is associated with SMAD3-related AOS, but
      the intervening mechanism remains unresolved.
  - target: Mitral Valve Prolapse
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Mitral valve disease is strongly associated with SMAD3-related LDS3, but
      the intervening valve-tissue mechanism is not resolved here.
- name: Reduced PRRX2-Dependent Aortic Microfibril Expression
  biological_scale: CELLULAR
  description: >-
    In a multigenerational SMAD3 p.Arg287Gln family, aortic smooth muscle cells
    showed reduced expression of microfibril genes and downregulation of PRRX2,
    a promoter-occupying regulator of five microfibril genes. SMAD3
    overexpression rescued both PRRX2 and microfibril expression, defining a
    directly tested SMAD3-PRRX2-microfibril axis.
  genes:
  - preferred_term: SMAD3
    term:
      id: hgnc:6769
      label: SMAD3
  - preferred_term: PRRX2
    term:
      id: hgnc:21338
      label: PRRX2
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: DECREASED
  evidence:
  - reference: PMID:42273728
    reference_title: "Microfibril Denudation Marks Early Aortic Vulnerability in SMAD3 Variant Carriers: A Multigenerational Study."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      RNA sequencing of Loeys-Dietz syndrome 3 SMCs revealed reduced
      microfibril gene expression.
    explanation: >-
      Patient-derived aortic SMC transcriptomics directly supports reduced
      microfibril-gene expression.
  - reference: PMID:42273728
    reference_title: "Microfibril Denudation Marks Early Aortic Vulnerability in SMAD3 Variant Carriers: A Multigenerational Study."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      SMAD3 overexpression rescued both PRRX2 and microfibril expression.
    explanation: >-
      Rescue by SMAD3 overexpression directly supports the direction of the
      SMAD3-PRRX2-microfibril regulatory relationship in patient-derived cells.
  downstream:
  - target: Aortic Smooth-Muscle-to-Elastic-Lamella Disconnection
    description: >-
      Reduced microfibril production leaves elastic fibers poorly sheathed and
      separates smooth muscle cells from the lamellae.
- name: Aortic Smooth-Muscle-to-Elastic-Lamella Disconnection
  biological_scale: TISSUE
  description: >-
    Early human aortic pathology in SMAD3 variant carriers consists of smooth
    muscle cells separated from elastic lamellae by glycosaminoglycans and
    elastic fibers that are poorly decorated by multiple microfibril proteins,
    even while lamellar structure and SMC content remain relatively intact.
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: DECREASED
  evidence:
  - reference: PMID:42273728
    reference_title: "Microfibril Denudation Marks Early Aortic Vulnerability in SMAD3 Variant Carriers: A Multigenerational Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, early pathology was evident, with SMCs separated from elastic
      lamellae by a thin layer of glycosaminoglycans. Confocal reconstructions
      revealed that elastic fibers were poorly decorated by microfibrils, with
      reduced fibrillin-1, fibrillin-2, microfibril associated glycoprotein-2,
      fibulin-1 and fibulin-2.
    explanation: >-
      Direct analysis of surgically obtained human aortas identifies an early
      tissue lesion preceding gross lamellar destruction.
  downstream:
  - target: Aortic Medial Degeneration and Wall Weakening
    description: >-
      Loss of smooth-muscle-to-elastic-lamella coupling and microfibril support
      creates an early structural vulnerability that contributes to medial
      degeneration.
- name: TGF-beta Signaling Dysregulation
  conforms_to: "aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation"
  biological_scale: CELLULAR
  description: >-
    Despite SMAD3 being a positive transducer of TGF-beta signaling, SMAD3
    mutations lead to paradoxically increased expression of key TGF-beta pathway
    components in the aortic wall, the same dysregulated-TGF-beta signature seen
    across the heritable thoracic aortic disease syndromes.
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: transforming growth factor beta receptor signaling pathway
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SMAD3 mutations lead to increased aortic expression of several key players
      in the TGF-β pathway, including SMAD3
    explanation: >-
      Demonstrates paradoxically increased aortic TGF-beta pathway signaling,
      the conserved aortopathy mechanism.
  - reference: PMID:27688095
    reference_title: "Defective Connective Tissue Remodeling in Smad3 Mice Leads to Accelerated Aneurysmal Growth Through Disturbed Downstream TGF-β Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Although Smad3-/- aortas showed increased nuclear pSmad2 and pErk,
      indicating TGF-β receptor activation, downstream TGF-β-activated target
      genes were not upregulated.
    explanation: >-
      Refines the TGF-beta paradox: in the Smad3-null model, receptor-proximal
      signaling (pSmad2, pErk) is increased while downstream SMAD3-dependent
      target-gene transcription fails.
  downstream:
  - target: Aortic Medial Degeneration and Wall Weakening
    description: >-
      Dysregulated TGF-beta signaling drives maladaptive medial remodeling.
- name: Aortic Medial Degeneration and Wall Weakening
  conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Medial Degeneration and Wall Weakening"
  biological_scale: TISSUE
  description: >-
    Dysregulated TGF-beta signaling together with the underlying connective
    tissue defect produces medial degeneration of the aortic wall. In the
    Smad3-null model the dominant findings are medial elastin (elastic fiber)
    disruption and adventitial inflammation with matrix metalloproteinase
    activation concentrated in inflammatory areas, progressively weakening the
    wall; this inflammatory, MMP-driven route is a notable AOS-specific feature.
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: ABNORMAL
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We delineated a new syndrome presenting with aneurysms, dissections and
      tortuosity throughout the arterial tree
    explanation: >-
      Establishes the systemic arterial-wall pathology (aneurysm, dissection,
      tortuosity) that reflects medial wall weakening.
  - reference: PMID:27688095
    reference_title: "Defective Connective Tissue Remodeling in Smad3 Mice Leads to Accelerated Aneurysmal Growth Through Disturbed Downstream TGF-β Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Aortic wall immunohistochemistry showed no increase in extracellular
      matrix and collagen accumulation, nor loss of vascular smooth muscle cells
      (VSMCs) but instead revealed medial elastin disruption and adventitial
      inflammation.
    explanation: >-
      Identifies medial elastin disruption and adventitial inflammation (rather
      than SMC loss or ECM accumulation) as the medial-degeneration mechanism in
      the Smad3-null aorta.
  - reference: PMID:23782924
    reference_title: "SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II-infused mice via activation of iNOS."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      the underlying mechanism involved aberrant upregulation of inducible
      nitric oxide synthase (iNOS)-derived nitric oxide production and activation
      of elastolytic matrix metalloproteinases 2 and 9
    explanation: >-
      Shows macrophage iNOS-derived nitric oxide and elastolytic MMP2/9
      activation as the mechanism of wall weakening in SMAD3-deficient aortas.
  downstream:
  - target: Progressive Arterial Aneurysm and Tortuosity
    description: Wall weakening permits progressive dilation and tortuosity.
- name: Progressive Arterial Aneurysm and Tortuosity
  conforms_to: "aortopathy_tgfbeta_dysregulation#Progressive Aortic Dilation and Aneurysm"
  biological_scale: ORGANISM
  description: >-
    Progressive weakening of the arterial wall produces aneurysms and marked
    tortuosity that, unlike Marfan syndrome, are distributed widely throughout
    the arterial tree rather than confined to the aortic root.
  biological_processes:
  - preferred_term: transforming growth factor beta receptor signaling pathway
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aneurysms, dissections and tortuosity throughout the arterial tree
    explanation: >-
      Documents the widespread arterial aneurysm and tortuosity phenotype.
  downstream:
  - target: Aortic Dissection and Rupture
    description: Aneurysmal, weakened arteries are prone to dissection and rupture.
  - target: Thoracic Aortic Aneurysm
    description: Progressive aortic wall weakening produces thoracic, usually root, aneurysm.
  - target: Arterial Tortuosity
    description: Diffuse arteriopathy produces tortuosity throughout the arterial tree.
  - target: Cerebral (Intracranial) Aneurysm
    description: The generalized arteriopathy includes intracranial arteries.
  - target: Visceral and Iliac Artery Aneurysm
    description: The generalized arteriopathy includes visceral and iliac arteries.
- name: Aortic Dissection and Rupture
  conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Dissection and Rupture"
  biological_scale: ORGANISM
  description: >-
    The weakened, aneurysmal arterial wall is prone to dissection and rupture.
    A clinically critical feature shared with other Loeys-Dietz subtypes is that
    dissection can occur at smaller aortic diameters and at younger ages than in
    Marfan syndrome, and vascular disease is not limited to the aortic root.
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aortic dissection can occur at smaller aortic diameters and at younger
      ages than observed in Marfan syndrome; vascular disease is not limited to
      the aortic root
    explanation: >-
      GeneReviews documents the high dissection risk at small diameters and the
      diffuse arterial involvement characteristic of Loeys-Dietz syndrome.
  - reference: PMID:22167769
    reference_title: "Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of the patients who first presented with joint abnormalities, 20% died
      suddenly from aortic dissection.
    explanation: >-
      Quantifies the lethal risk of aortic dissection in AOS, including in
      patients who initially presented with joint disease.
  - reference: PMID:30661052
    reference_title: "SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aortic events were documented in 37% of cases, with dissections
      accounting for 70% of events.
    explanation: >-
      In an international SMAD3 cohort, aortic events (dissection or aneurysm
      repair) affected a substantial minority, most being dissections.
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main cause of death was aortic dissection (9 of 15; 60%), which
      occurred at mildly increased aortic diameters (range: 40 to 63 mm).
    explanation: >-
      Aortic dissection was the leading cause of death and occurred at only
      mildly increased aortic diameters, underscoring dissection risk below
      conventional thresholds.
  downstream:
  - target: Aortic Dissection
    description: >-
      This clinical phenotype is the direct manifestation of the modeled
      dissection event.
- name: Cartilage TGF-beta Dysregulation and Early-Onset Osteoarthritis
  biological_scale: TISSUE
  description: >-
    A hallmark that distinguishes aneurysm-osteoarthritis syndrome from other
    aneurysm syndromes is prominent early-onset osteoarthritis, frequently with
    osteochondritis dissecans. SMAD3 is essential for TGF-beta-mediated
    regulation of chondrocyte differentiation and cartilage homeostasis, so its
    disruption promotes cartilage degeneration.
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: regulation of chondrocyte differentiation
    term:
      id: GO:0032330
      label: regulation of chondrocyte differentiation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast with other aneurysm syndromes, most of these affected
      individuals presented with early-onset osteoarthritis
    explanation: >-
      Establishes early-onset osteoarthritis as the distinctive musculoskeletal
      feature of the syndrome.
  downstream:
  - target: Early-Onset Osteoarthritis
    description: Cartilage dysregulation manifests as premature osteoarthritis.
  - target: Osteochondritis Dissecans
    description: >-
      Osteochondritis dissecans is part of the characteristic early joint-disease
      spectrum accompanying cartilage dysregulation.
phenotypes:
- name: Thoracic Aortic Aneurysm
  category: Cardiovascular
  description: >-
    Aneurysm of the thoracic aorta, typically involving the aortic root, is a
    core vascular manifestation.
  phenotype_term:
    preferred_term: Aortic root aneurysm
    term:
      id: HP:0002616
      label: Aortic root aneurysm
  frequency: FREQUENT
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thoracic aortic aneurysms and dissections are a main feature of connective
      tissue disorders
    explanation: >-
      Thoracic aortic aneurysm is a defining vascular feature of the syndrome.
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 71%, an aortic root aneurysm was found.
    explanation: >-
      In a cohort of 44 AOS patients, aortic root aneurysm was present in 71%,
      supporting a frequent occurrence.
- name: Aortic Dissection
  category: Cardiovascular
  description: >-
    Dissection of the aorta, which may occur at smaller diameters and younger
    ages than in Marfan syndrome.
  phenotype_term:
    preferred_term: Aortic dissection
    term:
      id: HP:0002647
      label: Aortic dissection
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aortic dissection can occur at smaller aortic diameters and at younger
      ages than observed in Marfan syndrome
    explanation: >-
      Documents aortic dissection and its occurrence at small diameters.
- name: Arterial Tortuosity
  category: Cardiovascular
  description: >-
    Tortuosity of arteries throughout the arterial tree, a characteristic
    feature of the syndrome.
  phenotype_term:
    preferred_term: Arterial tortuosity
    term:
      id: HP:0005116
      label: Arterial tortuosity
  frequency: FREQUENT
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aneurysms, dissections and tortuosity throughout the arterial tree
    explanation: >-
      Arterial tortuosity throughout the arterial tree is a hallmark feature.
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and in 48%, arterial tortuosity was diagnosed
    explanation: >-
      Arterial tortuosity was diagnosed in 48% of the AOS cohort.
- name: Cerebral (Intracranial) Aneurysm
  category: Cardiovascular
  description: >-
    Intracranial arterial aneurysms occur as part of the widespread arterial
    involvement.
  phenotype_term:
    preferred_term: Cerebral berry aneurysm
    term:
      id: HP:0007029
      label: Cerebral berry aneurysm
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      vascular findings (cerebral, thoracic, and abdominal arterial aneurysms
      and/or dissections)
    explanation: >-
      GeneReviews documents cerebral arterial aneurysms as part of the LDS
      vascular spectrum.
  - reference: PMID:22167769
    reference_title: "Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aneurysms and tortuosity were found in the aorta and other arteries
      throughout the body, including intracranial arteries.
    explanation: >-
      AOS-specific cohort documents intracranial arterial aneurysms as part of
      the widespread arterial involvement.
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cerebrovascular abnormalities were detected in 56% of
    explanation: >-
      In AOS patients undergoing cerebrovascular imaging, abnormalities were
      detected in the majority (56%), supporting frequent cerebrovascular
      involvement.
- name: Visceral and Iliac Artery Aneurysm
  category: Cardiovascular
  description: >-
    Aneurysms are widespread beyond the aorta, prominently involving the
    visceral (splanchnic) and iliac arteries. The common iliac artery is the
    most frequently affected branch, followed by superior mesenteric, celiac,
    and splenic arteries; early elective repair is recommended given very high
    rupture risk.
  phenotype_term:
    preferred_term: Iliac artery aneurysm
    term:
      id: HP:4000067
      label: Iliac artery aneurysm
  frequency: FREQUENT
  evidence:
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 33%, aneurysms in other arteries in the thorax and abdomen were
      diagnosed
    explanation: >-
      One third of the AOS cohort had aneurysms in arteries beyond the aortic
      root, in the thorax and abdomen.
  - reference: PMID:22975338
    reference_title: "Aneurysm-osteoarthritis syndrome with visceral and iliac artery aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The common iliac artery was most commonly affected (37%), followed by the
      superior mesenteric artery (15%), celiac trunk (11%), and splenic artery
      (9%).
    explanation: >-
      Quantifies the distribution of visceral and iliac artery aneurysms in AOS,
      with the common iliac artery most affected.
- name: Early-Onset Osteoarthritis
  category: Musculoskeletal
  description: >-
    Premature, often generalized osteoarthritis with onset in childhood or early
    adulthood is the distinctive musculoskeletal hallmark of the syndrome.
  phenotype_term:
    preferred_term: Osteoarthritis
    term:
      id: HP:0002758
      label: Osteoarthritis
    onset:
      onset_category: JUVENILE
  frequency: FREQUENT
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast with other aneurysm syndromes, most of these affected
      individuals presented with early-onset osteoarthritis
    explanation: >-
      Early-onset osteoarthritis is the distinguishing feature of the syndrome.
  - reference: PMID:22167769
    reference_title: "Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the majority of patients, early-onset joint abnormalities, including
      osteoarthritis and osteochondritis dissecans, were the initial symptom
      for which medical advice was sought.
    explanation: >-
      In the AOS phenotypic-spectrum cohort, early-onset osteoarthritis was the
      presenting feature in the majority of patients, supporting a very frequent
      occurrence.
- name: Osteochondritis Dissecans
  category: Musculoskeletal
  description: >-
    Osteochondritis dissecans and other joint lesions accompany the early-onset
    osteoarthritis.
  phenotype_term:
    preferred_term: Osteochondritis dissecans
    term:
      id: HP:0010886
      label: Osteochondritis dissecans
  evidence:
  - reference: PMID:22167769
    reference_title: "Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the majority of patients, early-onset joint abnormalities, including
      osteoarthritis and osteochondritis dissecans, were the initial symptom
      for which medical advice was sought.
    explanation: >-
      Osteochondritis dissecans is explicitly reported among the early-onset
      joint abnormalities of AOS.
- name: Hypertelorism
  category: Craniofacial
  description: Increased distance between the eyes, a mild craniofacial feature.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      craniofacial features (hypertelorism, strabismus, bifid uvula / cleft
      palate, and craniosynostosis that can involve any sutures)
    explanation: >-
      GeneReviews lists hypertelorism among the craniofacial features of LDS.
- name: Bifid Uvula or Cleft Palate
  category: Craniofacial
  description: Bifid uvula or cleft palate, a craniofacial marker of Loeys-Dietz syndrome.
  phenotype_term:
    preferred_term: Bifid uvula
    term:
      id: HP:0000193
      label: Bifid uvula
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bifid uvula / cleft palate
    explanation: >-
      Bifid uvula/cleft palate is a recognized craniofacial feature.
- name: Scoliosis
  category: Musculoskeletal
  description: Lateral curvature of the spine, part of the skeletal manifestations.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis,
      joint laxity, arachnodactyly, talipes equinovarus, and cervical spine
      malformation and/or instability)
    explanation: >-
      Scoliosis is listed among the skeletal manifestations of LDS.
- name: Pectus Deformity
  category: Musculoskeletal
  description: Pectus excavatum or carinatum chest wall deformity.
  phenotype_term:
    preferred_term: Pectus excavatum
    term:
      id: HP:0000767
      label: Pectus excavatum
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      skeletal manifestations (pectus excavatum or pectus carinatum
    explanation: >-
      Pectus deformity is a documented skeletal feature.
- name: Joint Laxity
  category: Musculoskeletal
  description: >-
    Generalized joint hypermobility/laxity, which coexists with the
    degenerative joint disease.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Loeys-Dietz syndrome (LDS) is characterized by vascular findings
      (cerebral, thoracic, and abdominal arterial aneurysms and/or dissections),
      skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis,
      joint laxity, arachnodactyly, talipes equinovarus, and cervical spine
      malformation and/or instability), craniofacial features (hypertelorism,
      strabismus, bifid uvula / cleft palate, and craniosynostosis that can
      involve any sutures), and cutaneous findings (velvety and translucent
      skin, easy bruising, and dystrophic scars).
    explanation: >-
      Joint laxity is listed among the skeletal manifestations of LDS.
- name: Thin or Translucent Skin
  category: Dermatologic
  description: >-
    Cutaneous fragility with velvety, thin/translucent skin, easy bruising, and
    dystrophic (atrophic) scars is part of the connective-tissue phenotype.
  phenotype_term:
    preferred_term: Thin skin
    term:
      id: HP:0000963
      label: Thin skin
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cutaneous findings (velvety and translucent skin, easy bruising, and
      dystrophic scars)
    explanation: >-
      GeneReviews documents thin/translucent skin, easy bruising, and dystrophic
      scars among the cutaneous features of Loeys-Dietz syndrome.
- name: Atrial Fibrillation
  category: Cardiovascular
  description: >-
    Atrial fibrillation is part of the cardiac phenotype of AOS, independent of
    the aortic disease.
  phenotype_term:
    preferred_term: Atrial fibrillation
    term:
      id: HP:0005110
      label: Atrial fibrillation
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cardiac abnormalities were diagnosed, such as congenital heart defects
      (6%), mitral valve abnormalities (51%), left ventricular hypertrophy
      (19%), and atrial fibrillation (22%).
    explanation: >-
      In the 44-patient AOS cohort, atrial fibrillation was present in 22%,
      which falls in the HPO OCCASIONAL band (5-29%).
- name: Left Ventricular Hypertrophy
  category: Cardiovascular
  description: >-
    Left ventricular hypertrophy is observed as part of the broader cardiac
    involvement in AOS.
  phenotype_term:
    preferred_term: Left ventricular hypertrophy
    term:
      id: HP:0001712
      label: Left ventricular hypertrophy
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cardiac abnormalities were diagnosed, such as congenital heart defects
      (6%), mitral valve abnormalities (51%), left ventricular hypertrophy
      (19%), and atrial fibrillation (22%).
    explanation: >-
      In the 44-patient AOS cohort, left ventricular hypertrophy was present in
      19%, which falls in the HPO OCCASIONAL band (5-29%).
- name: Mitral Valve Prolapse
  category: Cardiovascular
  description: >-
    Mitral valve prolapse and other mitral valve abnormalities are reported,
    and were noted to be prominent in SMAD3-related (type 3) Loeys-Dietz.
  phenotype_term:
    preferred_term: Mitral valve prolapse
    term:
      id: HP:0001634
      label: Mitral valve prolapse
  frequency: FREQUENT
  evidence:
  - reference: PMID:35662564
    reference_title: "Clinical features and complications of Loeys-Dietz syndrome: A systematic review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      LDS Type 3 demonstrated an increased prevalence of mitral valve prolapse
      and arthritis
    explanation: >-
      A systematic review reports increased mitral valve prolapse (and
      arthritis) specifically in SMAD3-related LDS type 3.
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mitral valve abnormalities (51%)
    explanation: >-
      Mitral valve abnormalities were present in 51% of the AOS cohort.
  - reference: PMID:38508323
    reference_title: "Cardiovascular pathology, inheritance and prognosis in a familial cohort of Loeys-Dietz type III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was significant intrafamilial phenotypic variability within the
      cohort with the predominant cardiovascular abnormality being mitral valve
      disease followed by aortic disease.
    explanation: >-
      An independently ascertained 2024 family cohort confirms that mitral valve
      disease can predominate and emphasizes intrafamilial variability.
- name: Arachnodactyly
  category: Musculoskeletal
  description: Long, slender digits are part of the overlapping LDS skeletal phenotype.
  phenotype_term:
    preferred_term: Arachnodactyly
    term:
      id: HP:0001166
      label: Arachnodactyly
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Loeys-Dietz syndrome (LDS) is characterized by vascular findings
      (cerebral, thoracic, and abdominal arterial aneurysms and/or dissections),
      skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis,
      joint laxity, arachnodactyly, talipes equinovarus, and cervical spine
      malformation and/or instability), craniofacial features (hypertelorism,
      strabismus, bifid uvula / cleft palate, and craniosynostosis that can
      involve any sutures), and cutaneous findings (velvety and translucent
      skin, easy bruising, and dystrophic scars).
    explanation: GeneReviews lists arachnodactyly among LDS skeletal manifestations.
- name: Pes Planus
  category: Musculoskeletal
  description: Flatfoot is a common skeletal manifestation in the SMAD3-related LDS spectrum.
  phenotype_term:
    preferred_term: Pes planus
    term:
      id: HP:0001763
      label: Pes planus
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Assess for skeletal deformity, joint manifestations, pes planus, hernia,
      and allergic and inflammatory manifestations at each visit or as needed.
    explanation: GeneReviews explicitly includes pes planus in LDS surveillance.
- name: Easy Bruising
  category: Dermatologic
  description: Easy bruising accompanies the cutaneous connective-tissue fragility.
  phenotype_term:
    preferred_term: Bruising susceptibility
    term:
      id: HP:0000978
      label: Bruising susceptibility
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cutaneous findings (velvety and translucent skin, easy bruising, and
      dystrophic scars)
    explanation: GeneReviews explicitly lists easy bruising among LDS cutaneous findings.
- name: Atrophic Scars
  category: Dermatologic
  description: Dystrophic or atrophic scarring is part of the cutaneous phenotype.
  phenotype_term:
    preferred_term: Atrophic scars
    term:
      id: HP:0001075
      label: Atrophic scars
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cutaneous findings (velvety and translucent skin, easy bruising, and
      dystrophic scars)
    explanation: GeneReviews explicitly lists dystrophic scarring among LDS cutaneous findings.
- name: Reduced Bone Mineral Density
  category: Musculoskeletal
  description: Reduced bone mass is increasingly recognized in SMAD3-related disease.
  phenotype_term:
    preferred_term: Reduced bone mineral density
    term:
      id: HP:0004349
      label: Reduced bone mineral density
  evidence:
  - reference: PMID:32154675
    reference_title: "Clinical and genetic data of 22 new patients with SMAD3 pathogenic variants and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our data underline the high prevalence of decreased bone mass in SRD and
      more generally in TGFβvs (Kirmani et al., 2010) that can become an
      important issue in patients care.
    explanation: >-
      A SMAD3 cohort/review reports a high prevalence of reduced bone mass;
      frequency is omitted because the quoted sentence does not provide a band.

discussions:
- discussion_id: arb_tgfbeta_target_uncertainty
  kind: CONTROVERSY
  status: OPEN
  prompt: >-
    Does angiotensin receptor blockade benefit SMAD3-related
    aneurysm-osteoarthritis syndrome by inhibiting aortic TGF-beta signaling,
    or only by reducing hemodynamic wall stress - and is TGF-beta the right
    therapeutic target in AOS at all?
  attaches_to:
  - pathophysiology#TGF-beta Signaling Dysregulation
  rationale: >-
    The entry models an ARB -> "TGF-beta Signaling Dysregulation" INHIBITS
    edge, but that edge is not directly evidenced in AOS. The GeneReviews
    statement attached to the ARB treatment supports only reduction of
    hemodynamic stress, not TGF-beta inhibition. Two SMAD3 mouse studies point
    away from TGF-beta as the actionable target: PMID:27688095 concludes that
    immune suppression may be more beneficial than targeting TGF-beta
    signaling, and PMID:23782924 nominates macrophage depletion and iNOS
    antagonism instead. The paradoxical-TGF-beta-increase model is inherited
    from the aortopathy_tgfbeta_dysregulation module and from Marfan/losartan
    biology, so there is a real risk of importing a mechanism that has not been
    demonstrated for SMAD3 specifically. Resolving this matters clinically,
    since ARB therapy is a modeled treatment for this disease.
  evidence:
  - reference: PMID:27688095
    reference_title: "Defective Connective Tissue Remodeling in Smad3 Mice Leads to Accelerated Aneurysmal Growth Through Disturbed Downstream TGF-β Signaling."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      instead of targeting TGF-β signaling, immune suppression may be more
      beneficial
    explanation: >-
      Argues against TGF-beta signaling as the therapeutic target in SMAD3
      aortic disease, in tension with the modeled ARB -> TGF-beta edge.
  - reference: PMID:23782924
    reference_title: "SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II-infused mice via activation of iNOS."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Macrophage depletion and iNOS antagonism represent 2 promising approaches
    explanation: >-
      Nominates immune/iNOS-directed rather than TGF-beta-directed intervention
      for SMAD3-related aneurysm.
  notes: >-
    Both refuting studies are MODEL_ORGANISM evidence, so they constrain the
    mechanistic claim rather than the clinical practice of using ARBs in AOS.
    Retained rather than deleting the target_mechanisms edge so the open
    question stays visible; a curator may prefer to retarget the edge to the
    hemodynamic-stress node instead.

diagnosis:
- name: Molecular confirmation of a pathogenic SMAD3 variant
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    Sequence analysis with deletion/duplication coverage, usually through a
    heritable thoracic aortic disease or connective-tissue multigene panel,
    identifies a heterozygous pathogenic or likely pathogenic SMAD3 variant.
    A variant of uncertain significance alone does not establish the diagnosis.
  results: >-
    A heterozygous pathogenic or likely pathogenic SMAD3 variant in a compatible
    clinical or family context establishes SMAD3-related LDS3/AOS.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of LDS is established in (1) a proband with characteristic
      clinical findings or (2) by the identification of a heterozygous
      pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2
    explanation: >-
      GeneReviews directly supports molecular confirmation and includes SMAD3.
- name: Baseline and serial whole-arterial-tree imaging
  diagnosis_term:
    preferred_term: Diagnostic Imaging Testing
    term:
      id: NCIT:C16502
      label: Diagnostic Imaging Testing
  description: >-
    Echocardiography measures the aortic root and ascending aorta, while
    contrast CT angiography or MR angiography from head to pelvis identifies
    extra-aortic aneurysms, dissections, and arterial tortuosity that
    echocardiography cannot detect.
  results: >-
    Aortic-root/ascending-aortic dimensions and the presence, location, and
    growth of aneurysm, dissection, or tortuosity establish vascular extent and
    guide surveillance and prophylactic repair.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Echocardiography to monitor the status of the aortic root and ascending
      aorta (at least annually) and magnetic resonance angiography or
      computerized tomography angiography to assess the entire arterial tree
    explanation: >-
      GeneReviews directly supports combined echocardiographic and complete
      arterial-tree imaging.

histopathology:
- name: Aortic Medial Degeneration
  description: >-
    Histology of human AOS aortic wall fragments shows disorganization of the
    tunica media with characteristic mucoid medial degeneration and
    accumulation of collagen in the media. This is the human tissue-level
    counterpart of the "Aortic Medial Degeneration and Wall Weakening"
    pathophysiology node.
  evidence:
  - reference: PMID:22975338
    reference_title: "Aneurysm-osteoarthritis syndrome with visceral and iliac artery aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On histology of aortic wall fragments, evident disorganization of the
      tunica media with fragmentation and loss of elastic fibers was observed,
      as well as characteristic mucoid medial degeneration and accumulation of
      collagen in media.
    explanation: >-
      Direct human aortic histology documenting mucoid medial degeneration and
      medial collagen accumulation in AOS.
  notes: >-
    Two caveats. (1) Human-versus-model discordance: the medial collagen
    accumulation seen in human AOS aortas is NOT recapitulated in the Smad3-/-
    mouse, where PMID:27688095 reports no collagen accumulation. The human
    histology above is therefore the primary support for this finding, and the
    mouse data should not be read as confirming it. (2) No finding_term is
    bound because the precise HPO aortic-histopathology terms (HP:0032079
    medial degeneration, HP:0200146 mucoid extracellular matrix accumulation)
    are not admissible under the current HistopathologyFindingTerm dynamic
    enum, which is reachable only from NCIT branches plus HP:0025461; NCIT has
    no equivalent term.
- name: Aortic Elastic Fiber Fragmentation and Loss
  description: >-
    Fragmentation and loss of medial elastic fibers accompanies the medial
    disorganization in AOS aortic wall specimens.
  evidence:
  - reference: PMID:22975338
    reference_title: "Aneurysm-osteoarthritis syndrome with visceral and iliac artery aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On histology of aortic wall fragments, evident disorganization of the
      tunica media with fragmentation and loss of elastic fibers was observed
    explanation: >-
      Human aortic histology documents elastic fiber fragmentation and loss.
  notes: >-
    No finding_term is bound: HP:0032083 (aortic elastic fiber fragmentation)
    is the exact term but is outside the HistopathologyFindingTerm enum's
    reachable set, and NCIT has no equivalent.

biochemical:
- name: N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)
  biomarker_term:
    preferred_term: NT-proBNP measurement
    term:
      id: NCIT:C96610
      label: N-Terminal ProB-type Natriuretic Peptide Measurement
  presence: Elevated relative to matched controls
  notes: >-
    NT-proBNP is elevated in AOS patients versus matched controls and correlates
    strongly with aortic pulse wave velocity, a measure of aortic stiffness.
  readouts:
  - target: Aortic Medial Degeneration and Wall Weakening
    relationship: CORRELATES_WITH
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      Higher NT-proBNP tracks with higher aortic pulse wave velocity (increased
      aortic stiffness), making it a candidate circulating correlate of the
      degenerated, stiffened aortic wall. This is an observed correlation in a
      single cohort, not a validated surrogate endpoint.
    evidence:
    - reference: PMID:22633655
      reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Aortic pulse wave velocity was high-normal (9.2 ± 2.2 m/s), indicating
        increased aortic stiffness, which strongly correlated with NT-proBNP
        (r = 0.731, p = 0.005).
      explanation: >-
        Quantifies the correlation between NT-proBNP and aortic stiffness in the
        AOS cohort.
  evidence:
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      N-terminal brain natriuretic peptide (NT-proBNP) was significantly higher
      in AOS patients compared with matched controls (p < 0.001).
    explanation: >-
      Establishes NT-proBNP elevation in AOS relative to matched controls.

genetic:
- name: SMAD3
  gene_term:
    preferred_term: SMAD3
    term:
      id: hgnc:6769
      label: SMAD3
  association: Causative
  relationship_type: CAUSATIVE
  notes: >-
    Heterozygous pathogenic variants in SMAD3, encoding the receptor-regulated
    SMAD3 of the TGF-beta pathway, cause aneurysm-osteoarthritis syndrome
    (Loeys-Dietz syndrome type 3). Inheritance is autosomal dominant. The
    variant spectrum includes haploinsufficiency alleles and missense
    substitutions in the MH2 domain (as well as MH1-domain variants and in-frame
    deletions); MH2 missense variants are associated with earlier aortic events.
    Penetrance for aortic disease is reduced and age of onset is variable.
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We mapped the genetic locus to chromosome 15q22.2-24.2 and show that the
      disease is caused by mutations in SMAD3
    explanation: >-
      Identifies SMAD3 (15q22) as the causal gene for the syndrome.
  - reference: PMID:30661052
    reference_title: "SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SMAD3 pathogenic variants cause thoracic aortic aneurysms and dissections
      in the majority of individuals with variable age of onset and reduced
      penetrance.
    explanation: >-
      Documents autosomal dominant SMAD3-driven aortic disease with variable
      onset and reduced penetrance.
  - reference: PMID:30661052
    reference_title: "SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median age at first aortic event was significantly lower in
      individuals with SMAD3 MH2 missense variants than those with HI variants
    explanation: >-
      Genotype-phenotype correlation: MH2-domain missense variants are
      associated with earlier aortic events than haploinsufficiency variants.
  - reference: DOI:10.1093/hmg/ddae044
    reference_title: Functional analysis of cell lines derived from SMAD3-related Loeys-Dietz syndrome patients provides insights into genotype-phenotype relation
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Individuals with dominant negative (DN) SMAD3 variant in the MH2 domain
      exhibited more major events (66.7% vs. 44.0%, P = 0.054), occurring at a
      younger age compared to those with haploinsufficient (HI) variants.
    explanation: >-
      The expanded cohort and patient-cell study supports a possible
      dominant-negative-versus-haploinsufficient distinction. The reported
      P=0.054 is borderline, so this is a risk-stratification signal rather than
      a definitive genotype-prognosis rule.
progression:
- phase: Childhood and adolescence
  age_range: Childhood to early adulthood
  notes: >-
    Early-onset joint disease (osteoarthritis and osteochondritis dissecans) is
    frequently the first manifestation, often prompting the initial medical
    evaluation. Aortic events in childhood have not been observed in SMAD3
    cohorts.
  evidence:
  - reference: PMID:22167769
    reference_title: "Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the majority of patients, early-onset joint abnormalities, including
      osteoarthritis and osteochondritis dissecans, were the initial symptom
      for which medical advice was sought.
    explanation: >-
      Establishes joint disease as the typical presenting feature earlier in the
      disease course.
  - reference: PMID:30661052
    reference_title: "SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No aortic events in childhood were observed.
    explanation: >-
      Supports the absence of aortic events during childhood, informing
      gene-specific surveillance.
- phase: Adulthood
  age_range: Adulthood
  notes: >-
    Aortic aneurysms and dissections accrue with age; the cumulative risk of an
    aortic event reaches 50% by age 54, and aortic dissection is a major cause
    of sudden death.
  evidence:
  - reference: PMID:30661052
    reference_title: "SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The cumulative risk of an aortic event was 50% at 54 years of age.
    explanation: >-
      Quantifies age-dependent cumulative aortic-event risk in the adult course.
  - reference: PMID:22167769
    reference_title: "Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of the patients who first presented with joint abnormalities, 20% died
      suddenly from aortic dissection.
    explanation: >-
      Documents sudden death from aortic dissection as a major adult outcome.
treatments:
- name: Angiotensin Receptor Blocker Therapy
  description: >-
    Angiotensin receptor blockers (e.g., losartan) are used to reduce
    hemodynamic stress and are hypothesized to attenuate dysregulated TGF-beta
    signaling in the aortic wall.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: losartan
      term:
        id: CHEBI:6541
        label: losartan
  target_mechanisms:
  - target: TGF-beta Signaling Dysregulation
    treatment_effect: INHIBITS
    description: >-
      Angiotensin receptor blockade (losartan) is proposed to attenuate the
      dysregulated aortic TGF-beta signaling that drives medial degeneration,
      in addition to lowering hemodynamic wall stress. IMPORTANT: this edge is
      a mechanistic hypothesis, not an evidenced effect in AOS. The attached
      GeneReviews evidence supports only the hemodynamic-stress rationale, and
      the SMAD3 mouse literature argues against TGF-beta as the actionable
      target. See discussion `arb_tgfbeta_target_uncertainty`.
  notes: >-
    Pregnancy contraindication. Angiotensin receptor blockers act on the
    renin-angiotensin system and are contraindicated in pregnancy because of
    fetal renal and developmental toxicity, so ARB therapy has to be reviewed
    and withdrawn before or at conception. This matters particularly in
    aneurysm-osteoarthritis syndrome, where the peripartum period itself
    carries a high risk of aortic dissection/rupture and uterine rupture and
    warrants intensified imaging instead (see the "Pregnancy and Peripartum
    Aortic Surveillance" treatment). Recorded as a note rather than as an
    evidence item because none of the cached references for this entry states
    the ARB pregnancy contraindication in quotable form.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      angiotensin receptor blockers, beta-adrenergic receptor blockers, or
      other medications are used to reduce hemodynamic stress
    explanation: >-
      GeneReviews documents angiotensin receptor blockers to reduce hemodynamic
      stress in LDS.
- name: Beta-Adrenergic Blocker Therapy
  description: >-
    Beta-adrenergic receptor blockers reduce hemodynamic stress on the aortic
    wall to slow aneurysm progression.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: beta-adrenergic antagonist
      term:
        id: NCIT:C29576
        label: Beta-Adrenergic Antagonist
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      angiotensin receptor blockers, beta-adrenergic receptor blockers, or
      other medications are used to reduce hemodynamic stress
    explanation: >-
      GeneReviews documents beta-adrenergic receptor blockers to reduce
      hemodynamic stress in LDS.
- name: Prophylactic Aortic and Arterial Surgery
  description: >-
    Aneurysms are amenable to early and aggressive surgical intervention;
    prophylactic repair at appropriate thresholds prevents dissection and
    rupture.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aneurysms are amenable to early and aggressive surgical intervention
    explanation: >-
      GeneReviews documents early, aggressive surgical repair of aneurysms in LDS.
  - reference: PMID:22633655
    reference_title: "Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dissections can occur at relatively mildly increased aortic diameters;
      therefore, early elective repair of the ascending aorta should be
      considered.
    explanation: >-
      Because dissection occurs at mildly increased diameters in AOS, early
      elective ascending-aorta repair is recommended.
- name: Avoidance of Contact, Competitive, and Isometric Exercise
  description: >-
    Patients should avoid contact and competitive sports and isometric exercise
    because these activities can impose abrupt hemodynamic stress on a fragile
    arterial wall.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Contact sports, competitive sports, and isometric exercise
    explanation: >-
      GeneReviews lists contact/competitive sports and isometric exercise among
      the agents/circumstances to avoid in Loeys-Dietz syndrome.
- name: Pregnancy and Peripartum Aortic Surveillance
  description: >-
    Pregnancy and the postpartum period are high-risk intervals in which aortic
    dissection/rupture and uterine rupture may occur, so aortic imaging is
    performed more frequently during gestation and in the weeks after delivery,
    and medical therapy is reviewed for fetal safety.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  notes: >-
    Curated as management rather than as a phenotype because the cited source
    states a peripartum surveillance recommendation. The evidence is
    Loeys-Dietz-syndrome-wide GeneReviews guidance, which covers SMAD3-related
    LDS type 3 (aneurysm-osteoarthritis syndrome) but is not SMAD3-specific.
    Angiotensin receptor blocker therapy is contraindicated in pregnancy and
    must be reviewed in this setting; see the notes on "Angiotensin Receptor
    Blocker Therapy".
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pregnancy and the postpartum period can be dangerous for women with LDS
      because of increased risk of aortic dissection/rupture and uterine
      rupture. Increased frequency of aortic imaging is recommended, both
      during pregnancy and in the weeks following delivery.
    explanation: >-
      GeneReviews documents the peripartum aortic-catastrophe and
      uterine-rupture risk in Loeys-Dietz syndrome and the intensified aortic
      imaging schedule it warrants.
prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >-
    Aneurysm-osteoarthritis syndrome (SMAD3-related Loeys-Dietz syndrome type 3)
    is a rare disorder; a precise population prevalence has not been
    established. The only quantitative anchor available is the share of
    familial thoracic aortic aneurysm and dissection attributable to AOS (~2%),
    which is a disease-fraction rather than a population rate. The incidence of
    AOS among patients with primary visceral and iliac artery aneurysms is
    explicitly stated to be unknown.
  evidence:
  - reference: PMID:22975338
    reference_title: "Aneurysm-osteoarthritis syndrome with visceral and iliac artery aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AOS is estimated to be responsible for ~2% of familial thoracic aortic
      aneurysms and dissections
    explanation: >-
      Provides the only quantitative occurrence anchor for AOS: a ~2% share of
      familial thoracic aortic aneurysm and dissection. Population prevalence
      remains undetermined, so prevalence_class stays UNKNOWN.
experimental_models:
- name: Patient-Derived SMAD3 Fibroblast and Vascular Smooth Muscle Cell Cultures
  description: >-
    Primary fibroblasts and vascular smooth muscle cells from individuals with
    pathogenic/likely pathogenic SMAD3 variants were compared across
    dominant-negative MH2 and haploinsufficient variant classes. The system
    resolves variant-class effects on differentiation, smooth-muscle markers,
    MYH11 isoforms, and extracellular-matrix formation. It is limited by small
    numbers of patient lines, in-vitro differentiation, and the borderline
    clinical genotype-event comparisons; it does not reproduce arterial
    biomechanics, immune recruitment, or longitudinal aneurysm formation.
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  cell_source: Primary patient-derived dermal fibroblasts and vascular smooth muscle cells
  culture_system: Monolayer culture with fibroblast-to-myofibroblast differentiation
  conditions:
  - dominant-negative SMAD3 MH2-domain variants
  - haploinsufficient SMAD3 variants
  - control cell lines
  publication: DOI:10.1093/hmg/ddae044
  modeled_mechanisms:
  - target: SMAD3 Loss-of-Function
    description: >-
      Compares functional consequences of dominant-negative and
      haploinsufficient pathogenic SMAD3 variants.
    evidence:
    - reference: DOI:10.1093/hmg/ddae044
      reference_title: Functional analysis of cell lines derived from SMAD3-related Loeys-Dietz syndrome patients provides insights into genotype-phenotype relation
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Pathogenic (P)/likely pathogenic (LP) SMAD3 variants cause Loeys-Dietz
        syndrome type 3 (LDS3), which is characterized by arterial aneurysms,
        dissections and tortuosity throughout the vascular system combined with
        osteoarthritis.
      explanation: >-
        Establishes pathogenic SMAD3 variants as the genetic cause represented
        by the primary-cell model.
  - target: Aortic Medial Degeneration and Wall Weakening
    description: >-
      Measures vascular smooth-muscle differentiation and extracellular-matrix
      outputs relevant to aortic wall homeostasis.
    evidence:
    - reference: DOI:10.1093/hmg/ddae044
      reference_title: Functional analysis of cell lines derived from SMAD3-related Loeys-Dietz syndrome patients provides insights into genotype-phenotype relation
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        DN SMAD3 variant myofibroblasts demonstrated reduced extracellular
        matrix formation compared to control cell lines.
      explanation: >-
        Directly supports the model's extracellular-matrix readout relevant to
        medial wall integrity, without claiming that the culture reproduces the
        intact aorta.
  findings:
  - statement: >-
      Dominant-negative and haploinsufficient SMAD3 variants produced distinct
      differentiation, smooth-muscle-marker, MYH11-isoform, and matrix phenotypes.
    supporting_text: >-
      Fibroblasts carrying DN SMAD3 variants displayed reduced differentiation
      potential, contrasting with increased differentiation potential in HI
      SMAD3 variant fibroblasts.
    evidence:
    - reference: DOI:10.1093/hmg/ddae044
      reference_title: Functional analysis of cell lines derived from SMAD3-related Loeys-Dietz syndrome patients provides insights into genotype-phenotype relation
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Fibroblasts carrying DN SMAD3 variants displayed reduced differentiation
        potential, contrasting with increased differentiation potential in HI
        SMAD3 variant fibroblasts.
      explanation: >-
        Directly states the opposing differentiation phenotypes of the two
        pathogenic-variant classes.
  evidence:
  - reference: DOI:10.1093/hmg/ddae044
    reference_title: Functional analysis of cell lines derived from SMAD3-related Loeys-Dietz syndrome patients provides insights into genotype-phenotype relation
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      A retrospective analysis on clinical data from individuals with a P/LP
      SMAD3 variant and functional analyses on SMAD3 patient-derived VSMCs and
      SMAD3 patient-derived fibroblasts, differentiated into myofibroblasts.
    explanation: >-
      Defines the patient-derived primary-cell systems and the fibroblast
      differentiation design.
datasets: []
📚

References & Deep Research

References

1
PMID:20301312
Loeys-Dietz Syndrome.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Aneurysm–osteoarthritis syndrome (SMAD3-related Loeys–Dietz syndrome type 3): mechanism, phenotype, and management
Edison Scientific Literature 44 citations 2026-07-29T22:45:49.895511

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Provide a comprehensive, mechanism-focused review of aneurysm-osteoarthritis syndrome (AOS), also known as Loeys-Dietz syndrome type 3 (LDS3) / Loeys-Dietz syndrome type 1C, caused by heterozygous germline mutations in SMAD3 (OMIM 613795; MONDO:0013426; Orphanet 284984).

Focus on: 1. Molecular pathophysiology: SMAD3 loss-of-function/haploinsufficiency, its role in canonical TGF-beta signaling (R-SMAD, SMAD4 complex), and the paradoxical increase in aortic-wall TGF-beta signaling; medial degeneration mechanisms. 2. Vascular phenotypes: thoracic aortic aneurysm and dissection, arterial tortuosity, aneurysms/dissections of other arteries (intracranial, iliac, splenic), risk of dissection at small aortic diameters. 3. The distinctive musculoskeletal phenotype: early-onset osteoarthritis and osteochondritis dissecans, spectrum of joint involvement, age of onset. 4. Craniofacial, skeletal, cutaneous, and other systemic features. 5. Genetics: SMAD3 variant spectrum, inheritance (autosomal dominant), penetrance, genotype-phenotype correlations, de novo vs familial. 6. Diagnosis, surveillance, and management: imaging surveillance, medical therapy (beta blockers, angiotensin receptor blockers/losartan), surgical thresholds, agents/circumstances to avoid. 7. Epidemiology/prevalence and natural history/prognosis (life expectancy, dissection risk).

For every key assertion, cite the primary literature with PubMed IDs (PMIDs) and provide exact quotable sentences from the abstracts. Include the seminal van de Laar et al. 2011 Nature Genetics paper and subsequent cohort/genotype-phenotype studies.

Aneurysm–osteoarthritis syndrome (SMAD3-related Loeys–Dietz syndrome type 3): mechanism, phenotype, and management

Executive summary

Aneurysm–osteoarthritis syndrome (AOS; LDS3) is a rare autosomal-dominant heritable thoracic aortic disease caused by heterozygous pathogenic variants in SMAD3 (OMIM phenotype 613795; MONDO:0013426; Orphanet 284984). Its defining combination is an aggressive, generalized arteriopathy—thoracic aortic aneurysm/dissection, arterial tortuosity, and aneurysms or dissections in cerebral, visceral, and iliac vessels—with unusually early osteoarthritis and sometimes osteochondritis dissecans. Craniofacial, skeletal, and cutaneous signs overlap other Loeys–Dietz syndromes but may be subtle or absent.

SMAD3 is a receptor-regulated SMAD (R-SMAD) in canonical TGF-β signaling. Ligand-activated TGFBR2/TGFBR1 phosphorylates SMAD2/3; phosphorylated R-SMADs complex with SMAD4, enter the nucleus, and regulate extracellular-matrix turnover, proliferation, differentiation, apoptosis, motility, and adhesion. Pathogenic alleles can produce haploinsufficiency or dominant-negative proteins. Counterintuitively, diseased aortic walls may exhibit increased nuclear pSMAD2 and ERK despite deficient SMAD3-dependent transcription—the “TGF-β paradox.” Current evidence favors a spatially and temporally heterogeneous failure of matrix-preserving signaling, accompanied by maladaptive compensatory receptor signaling, smooth-muscle-cell dysfunction, elastin injury, inflammation, and protease activity, rather than a simple state of globally excessive TGF-β signaling. (pluijm2016defectiveconnectivetissue pages 9-10, pluijm2016defectiveconnectivetissue pages 1-2, wagenaar2024functionalanalysisof pages 1-3)

1. Definition and nomenclature

The 2011 discovery paper by van de Laar and colleagues established heterozygous SMAD3 mutations as the cause of a syndromic aortopathy with early-onset osteoarthritis: Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis, published February 2011 in Nature Genetics 43:121–126; DOI 10.1038/ng.744; PMID 21217753. The abstract itself was unavailable through the retrieved corpus, so no purported verbatim sentence from it is supplied. Its title is itself the concise discovery claim. Subsequent nomenclature places this condition within Loeys–Dietz syndrome as LDS type 3; “LDS type 1C” is an older classification.

A recent primary study states verbatim: “Pathogenic (P) and likely pathogenic (LP) variants in the SMAD3 gene cause Loeys-Dietz syndrome type 3 (LDS3), also known as aneurysms-osteoarthritis syndrome (AOS).” It further describes a highly variable phenotype comprising “arterial aneurysms, dissections and tortuosity throughout the vascular system combined with skeletal, cutaneous and facial features.” (wagenaar2024functionalanalysisof pages 1-3)

2. Molecular pathophysiology

2.1 Canonical TGF-β–SMAD signaling

SMAD3 contains an N-terminal MH1 DNA-binding domain, a linker, and a C-terminal MH2 domain that mediates receptor phosphorylation, oligomerization, protein interactions, and transcriptional activation. The canonical sequence is:

  1. TGF-β ligand binds a TGFBR2/TGFBR1 receptor complex.
  2. The activated type I receptor phosphorylates SMAD2 and SMAD3, the R-SMADs.
  3. Phosphorylated SMAD2/3 associates with the common mediator SMAD4.
  4. The complex accumulates in the nucleus and cooperates with DNA-binding partners, coactivators, and corepressors.
  5. Target programs regulate extracellular matrix, VSMC differentiation and contractility, proliferation, apoptosis, motility, adhesion, and inflammatory restraint.

The 2024 patient-cell study summarizes this directly: “Upon activation by binding of TGF-β, the TGF-β receptor complex activates SMAD3 and SMAD2 proteins (receptor-regulated Smads; R-SMADs) by phosphorylation. Once phosphorylated, the R-SMADs can form a protein complex with SMAD4 (co-SMAD).” (wagenaar2024functionalanalysisof pages 1-3)

2.2 Loss of function, haploinsufficiency, and dominant-negative effects

The known variant spectrum includes missense, nonsense, frameshift, splice-altering variants, intragenic deletions, and whole-gene deletions. More than 60 pathogenic/likely pathogenic variants had been described by the recent functional study; there is no single mutational hotspot, although many pathogenic missense variants cluster in MH2. Truncating, splice variants subject to nonsense-mediated decay, and deletions commonly cause haploinsufficiency. Some missense variants produce stable proteins that interfere with receptor activation, SMAD4-complex formation, DNA regulation, or wild-type SMAD3 function and are therefore functionally dominant negative. (wagenaar2024functionalanalysisof pages 1-3, wagenaar2024functionalanalysisof pages 3-6)

The newest genotype–phenotype evidence suggests that mechanism and domain matter. In the 2024 study, individuals with dominant-negative MH2 variants had major events in 66.7%, versus 44.0% with haploinsufficient variants (p=0.054); median age at first major event was 35.0 years (IQR 29–47) versus 46.0 years (IQR 40–54; p=0.065). These are trends rather than conventionally significant results and require replication. Patient-derived dominant-negative myofibroblasts formed less ECM, whereas haploinsufficient cells showed different differentiation, SMA, and MYH11-isoform abnormalities. (wagenaar2024functionalanalysisof pages 1-3)

Exact abstract quotation: “Individuals with dominant negative (DN) variants in the MH2 protein interaction domain of SMAD3 exhibited a higher frequency of major events (66.7% vs. 44.0%, p=0.054), occurring at a younger age compared to those with haploinsufficient (HI) variants.” (wagenaar2024functionalanalysisof pages 1-3)

2.3 The paradox of increased aortic-wall signaling

A loss-of-function mutation in a canonical signaling effector might be expected to reduce signaling. Yet surgical tissue and Smad3-deficient models can show increased pSMAD2 and ERK, interpreted as increased receptor-proximal canonical and noncanonical activation. This does not demonstrate intact or globally excessive SMAD3-mediated transcription. In Smad3-null aortas, pSMAD2 and pERK increased while canonical target genes such as FN1, PAI1, SMAD7, SMAD6, and TIMP1 were not appropriately induced or were reduced. Thus, upstream compensatory activation and alternative-SMAD/noncanonical signaling coexist with defective SMAD3-dependent output. (pluijm2016defectiveconnectivetissue pages 9-10, pluijm2016defectiveconnectivetissue pages 1-2)

Exact abstract quotation: “Although Smad3−/− aortas showed increased nuclear pSmad2 and pErk, indicating TGF-β receptor activation, downstream TGF-β-activated target genes were not upregulated.” (pluijm2016defectiveconnectivetissue pages 1-2)

Mechanistically plausible contributors include increased ligand availability after matrix injury, compensatory receptor activation, signaling through residual SMAD2, ERK/JNK pathways, inflammatory-cell signaling, altered feedback inhibition, and late secondary signaling in already damaged tissue. Accordingly, pSMAD staining in end-stage aorta should not be equated with the initiating lesion or used as proof that systemic TGF-β inhibition will be beneficial.

2.4 Medial degeneration and inflammatory amplification

AOS aortopathy is a multicellular failure of wall homeostasis:

  • impaired VSMC differentiation/contractility and abnormal biomechanics;
  • defective matrix-preserving transcription and ECM assembly;
  • elastic-lamellar fragmentation and medial disorganization;
  • altered VSMC proliferation;
  • adventitial and medial inflammatory recruitment;
  • macrophage-derived nitric oxide and protease activation;
  • progressive loss of wall tensile integrity, dilation, dissection, and rupture.

In Smad3-null mice, pre-aneurysmal aortas already showed altered medial VSMC appearance, elastin disruption, and increased pSMAD2/pERK before conspicuous inflammatory infiltration. Later aneurysms showed adventitial inflammation and MMP activity concentrated in inflammatory regions rather than intrinsic activation within VSMCs. (pluijm2016defectiveconnectivetissue pages 9-10, pluijm2016defectiveconnectivetissue pages 1-2)

Exact abstract quotations include: “Aortic wall immunohistochemistry showed no increase in extracellular matrix and collagen accumulation, nor loss of vascular smooth muscle cells (VSMCs) but instead revealed medial elastin disruption and adventitial inflammation.” Also, “Increased pSmad2 and pErk staining in pre-aneurysmal Smad3−/− aortas implied that aortic damage and TGF-β receptor-activated signaling precede aortic inflammation.” (pluijm2016defectiveconnectivetissue pages 1-2)

A complementary AngII-infused mouse study found that inflammation rather than pressure elevation alone was decisive. SMAD3 deficiency impaired biomechanics and enabled macrophage iNOS-derived nitric oxide to activate elastolytic MMP2/9. Its abstract states: “We have shown that angiotensin II–induced vascular inflammation, but not hypertension, leads to aortic aneurysms and dissections, ultimately causing aortic rupture and death in mice.” It also reports that the mechanism “involved aberrant upregulation of inducible nitric oxide synthase (iNOS)–derived nitric oxide production and activation of elastolytic matrix metalloproteinases 2 and 9.” These findings identify investigational pathways, not established human treatments. (tan2013smad3deficiencypromotes pages 1-2)

3. Vascular phenotype and natural history

3.1 Aorta

The characteristic lesion is aortic-root or ascending-thoracic aneurysm, but disease can involve every aortic segment. Type A and type B dissections, postoperative distal disease, and recurrent aneurysms are recognized. Aortic disease can begin in childhood or infancy, although many first events occur in adulthood.

Early cohorts described an aggressive cardiovascular course and approximately 90% cumulative occurrence of aortic aneurysm/dissection among ascertainment-enriched mutation carriers. The Tan abstract states: “Ninety percent of the patients carrying distinct SMAD3 mutations develop aortic aneurysms and dissections, called aneurysms-osteoarthritis syndrome (AOS).” This figure should not be treated as an unbiased population penetrance estimate: original families were discovered through aortic disease, manifestations are age dependent, and modern cascade testing identifies milder carriers. (tan2013smad3deficiencypromotes pages 1-2)

A critical clinical feature is that dissection may occur at diameters below conventional thresholds used for degenerative aneurysm. Risk assessment must therefore incorporate genotype, family history, growth rate, body size, sex, pregnancy plans, arterial tortuosity, and prior dissection—not diameter alone.

3.2 Generalized arteriopathy

AOS is not confined to the thoracic aorta. Reported disease includes:

  • tortuosity of cervical, intracranial, aortic, and visceral arteries;
  • intracranial aneurysms and occasional cerebrovascular dissections;
  • common/internal iliac aneurysms and dissections;
  • splenic and other visceral-artery aneurysms;
  • renal, hepatic, mesenteric, carotid, subclavian, and peripheral arterial lesions in individual patients.

This distribution underlies the requirement for head-to-pelvis imaging rather than echocardiography alone. The 2024 study’s abstract explicitly characterizes disease as occurring “throughout the vascular system.” (wagenaar2024functionalanalysisof pages 1-3)

Key follow-up primary reports include van der Linde et al., Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants, JACC, July 2012, DOI 10.1016/j.jacc.2011.12.052; and van der Linde et al., Aneurysm-osteoarthritis syndrome with visceral and iliac artery aneurysms, Journal of Vascular Surgery, January 2013, DOI 10.1016/j.jvs.2012.06.107. Their abstracts were not available in the retrieved text, so exact abstract quotations are not fabricated.

4. Distinctive musculoskeletal phenotype

4.1 Early-onset osteoarthritis

Premature osteoarthritis is the clinical feature that originally distinguished AOS from other syndromic aortopathies. It can precede recognition of vascular disease and may occur during adolescence or early adulthood, decades earlier than typical primary OA. Conversely, young carriers may not yet have OA, and some adults with pathogenic variants have little or no symptomatic OA; absence therefore does not exclude LDS3.

Commonly involved sites include knees, hips, spine, hands/fingers, wrists, shoulders, ankles, and feet. Clinical consequences include pain, stiffness, restricted movement, meniscal disease, degenerative spinal disease, and early joint-replacement surgery in severe cases. The 2011 discovery paper’s title provides the foundational formulation: “with early-onset osteoarthritis.” The 2024 molecular paper likewise defines LDS3 as aneurysms/tortuosity “accompanied by osteoarthritis.” (wagenaar2024functionalanalysisof pages 3-6, asta2023geneticbasisnew pages 14-15)

4.2 Osteochondritis dissecans and joint mechanism

Osteochondritis dissecans—especially at the knee and ankle—has been repeatedly reported, as have meniscal abnormalities. Mechanistically, SMAD3 is necessary for chondrocyte homeostasis, controlled matrix turnover, and integration of signals between cartilage, subchondral bone, and synovium. Reduced SMAD3 signaling can shift chondrocytes toward hypertrophy and catabolism, impair cartilage-matrix maintenance, and disturb osteochondral remodeling. Mechanical loading then amplifies damage. This joint phenotype and the aortic phenotype are therefore parallel consequences of failed TGF-β/SMAD3-dependent connective-tissue homeostasis rather than unrelated comorbidities.

5. Other systemic manifestations

Expression is variable, and no physical sign is required when a pathogenic SMAD3 variant is established.

  • Craniofacial: hypertelorism, long or narrow face, high-arched or cleft palate, bifid/broad uvula, micrognathia or retrognathia, and craniosynostosis in occasional patients.
  • Skeletal: scoliosis, kyphosis, pectus excavatum/carinatum, pes planus, arachnodactyly, joint hypermobility or contractures, spondylolisthesis, and cervical-spine abnormalities.
  • Cutaneous: thin or translucent skin, easy bruising, visible veins, abnormal or widened scars, and striae.
  • Cardiac/other: mitral-valve prolapse or regurgitation, bicuspid aortic valve and congenital heart defects in a minority; dural ectasia, hernias, spontaneous pneumothorax, allergic/inflammatory disease, and gastrointestinal manifestations occur across the broader LDS spectrum.

Ectopia lentis, a hallmark of Marfan syndrome, is not characteristic of LDS. The systemic phenotype can be mild enough that a patient first presents with dissection or familial cascade testing. Recent primary evidence summarizes the relevant categories as “skeletal, cutaneous and facial features.” (wagenaar2024functionalanalysisof pages 1-3)

6. Genetics

6.1 Inheritance and testing

AOS is autosomal dominant. An affected heterozygous person has a 50% probability of transmitting the variant in each pregnancy. Most reported cases belong to multigenerational families, although de novo pathogenic variants occur; parental testing is necessary to distinguish a truly de novo event from unrecognized mild disease or parental mosaicism.

Testing should use a validated HTAD multigene panel with sequencing and deletion/duplication analysis. A pathogenic/likely pathogenic SMAD3 variant establishes the molecular diagnosis in the appropriate clinical context. A variant of uncertain significance must not be used alone for irreversible surgery or predictive testing. Cascade testing should be offered to first-degree relatives, with vascular imaging for carriers and for at-risk relatives whose genetic status remains unresolved.

6.2 Penetrance and variable expressivity

Vascular penetrance is high but age dependent; penetrance of OA and external signs is incomplete. Severe intrafamilial variation is common. A child with the familial variant may have normal dimensions, whereas an older relative may have widespread aneurysms or prior dissection. This variability likely reflects variant mechanism/domain, sex, ancestry, blood pressure, smoking, mechanical load, pregnancy, and unidentified genetic modifiers. (wagenaar2024functionalanalysisof pages 3-6)

6.3 Genotype–phenotype correlations

The most credible emerging correlation is earlier major/aortic events with dominant-negative MH2 variants compared with haploinsufficient alleles. However, the 2024 comparisons did not cross the conventional p<0.05 threshold; they should inform vigilance, not determine management in isolation. No variant class reliably predicts freedom from cerebral/visceral disease or OA. (wagenaar2024functionalanalysisof pages 1-3)

7. Diagnosis and surveillance

7.1 Initial evaluation

Recommended evaluation in an experienced multidisciplinary HTAD center includes:

  1. Three-generation pedigree documenting aneurysm location, dissection diameter and age, sudden death, surgery, cerebrovascular events, and early OA.
  2. Examination for LDS craniofacial, skin, skeletal, and joint signs.
  3. Baseline transthoracic echocardiography of the aortic root/ascending aorta and valves.
  4. ECG-gated CTA or MRA from head/cerebral circulation through pelvis to assess the entire aorta and branch arteries.
  5. Musculoskeletal assessment when pain, locking, reduced motion, or suspected osteochondritis dissecans is present.
  6. Molecular confirmation and cascade testing.

A 2023 review summarizes contemporary guidance as “whole body imaging (from cerebral circulation to pelvis) in all patients with LDS at diagnosis and six monthly afterwards to establish if enlargement is occurring.” (monda2023theroleof pages 6-7)

7.2 Longitudinal imaging

A practical regimen is echocardiography approximately six months after diagnosis to establish growth rate and then at least annually if stable; shorter intervals are appropriate with dilation, rapid growth, pregnancy, a family history of small-diameter dissection, or a new lesion. Cross-sectional head-to-pelvis CTA/MRA should be repeated after approximately 6–12 months and then every 1–2 years when stable, individualized by findings. MRA is preferred when feasible for repeated surveillance to reduce cumulative radiation, whereas ECG-gated CTA is useful for urgent assessment, small branches, stents, and surgical planning. Imaging should be performed with consistent technique and measurements.

8. Management

8.1 Medical therapy

Treatment aims to reduce pulsatile wall stress and control modifiable risk:

  • Beta blockers reduce heart rate, contractility, and dP/dt.
  • Angiotensin-receptor blockers, commonly losartan, reduce blood pressure and may modulate AngII/TGF-β/ERK signaling.
  • Either or both are reasonable from diagnosis, titrated to tolerability and blood-pressure/heart-rate goals.
  • Treat hypertension aggressively; stop smoking and manage lipids and other vascular risks.

The evidence for beta blockers/ARBs in LDS3 specifically is extrapolated mainly from Marfan/LDS biology and observational experience; no adequately powered SMAD3-specific randomized trial demonstrates prevention of dissection. A 2023 review states: “Currently, 2022 ACC/AHA guidelines for aortic disease recommend starting beta-blockers and/or ARBs at the time of diagnosis in order to reduce aortic growth rate and reduce the occurrence of aortic events.” (monda2023theroleof pages 6-7)

Losartan’s proposed pathway effect is summarized as reducing SMAD2 phosphorylation and inhibiting ERK2, but this does not resolve the TGF-β paradox or prove a genotype-specific clinical effect. (asta2023geneticbasisnew pages 12-14)

8.2 Prophylactic surgery

Elective aortic-root/ascending replacement should be decided by a multidisciplinary aortic team. For SMAD3-related LDS, a threshold around 4.5 cm is commonly considered, with earlier intervention—approximately 4.0–4.5 cm—when high-risk features are present. Relevant modifiers include family dissection at small diameter, rapid growth, marked tortuosity, severe systemic features, female sex/small body size, planned pregnancy, significant valve disease, and a potentially high-risk genotype. Diameter must be indexed and interpreted in context; a rigid threshold is inappropriate.

Valve-sparing root replacement is preferred when anatomy and expertise permit. Distal or branch-vessel repair is individualized. Native-tissue fragility and progressive adjacent disease require lifelong postoperative imaging.

8.3 Circumstances and agents to avoid

  • Avoid heavy isometric exertion, maximal lifting, straining/Valsalva, collision sports, and exercise causing extreme blood-pressure surges. Moderate dynamic exercise is generally favored after individualized assessment; a 2024 review states, “Generally, power exercises are not recommended.” (spaziani2024hereditarythoracicaortic pages 12-13, spaziani2024hereditarythoracicaortic pages 13-15)
  • Avoid uncontrolled hypertension and stimulants that markedly raise blood pressure.
  • Fluoroquinolones should generally be avoided when reasonable alternatives exist because of regulatory warnings about aneurysm/dissection risk in predisposed patients.
  • Endovascular stent-grafting in native connective-tissue aorta is generally avoided as routine definitive treatment because of progressive dilation, endoleak, and landing-zone failure; it may be used in emergencies or when landing zones are within surgical grafts. (monda2023theroleof pages 6-7, spaziani2024hereditarythoracicaortic pages 12-13)
  • ARBs and ACE inhibitors are contraindicated in pregnancy because of fetal toxicity. (spaziani2024hereditarythoracicaortic pages 12-13)

8.4 Pregnancy

Preconception counseling and complete aortic imaging are essential. Pregnancy increases hemodynamic and hormonal stress, and risk persists postpartum. Management should involve maternal–fetal medicine, cardiology, genetics, anesthesia, and aortic surgery. Beta blockade is commonly continued with fetal-growth monitoring; ARBs must be stopped before conception. Imaging is repeated during pregnancy according to aortic size and risk, and again postpartum. Prophylactic surgery before pregnancy should be considered at lower diameters than in otherwise comparable nonpregnant patients. (spaziani2024hereditarythoracicaortic pages 12-13)

9. Epidemiology and prognosis

Population prevalence is unknown. AOS is very rare and probably underdiagnosed because external features may be mild, OA may be attributed to common degenerative disease, and sudden dissection may precede syndromic recognition. Published cohorts are referral- and family-ascertainment enriched, so percentages cannot be generalized directly to all carriers.

Untreated prognosis is dominated by aortic or arterial dissection, rupture, and complications of repeated vascular interventions. Events can occur in childhood but more often emerge in adult life; the 2024 genotype–phenotype cohort places median first major events in the fourth to fifth decades depending on variant mechanism. Life expectancy cannot be summarized by one reliable SMAD3-specific number. It is likely shortened without recognition, but early genetic diagnosis, lifelong whole-arterial-tree surveillance, pressure-reducing therapy, and timely elective surgery substantially improve outlook. Statements that all LDS patients have a mean age of death near 26 years derive largely from early, severe, mixed-genotype LDS series and should not be applied as an LDS3 life-expectancy estimate. (wagenaar2024functionalanalysisof pages 1-3, asta2023geneticbasisnew pages 12-14)

10. Current research interpretation

The most important recent advance is movement away from treating all SMAD3 variants as functionally equivalent. Patient-derived VSMC and myofibroblast studies now distinguish dominant-negative from haploinsufficient effects on differentiation, contractile markers, MYH11 isoforms, and ECM formation. The reported earlier-event trend for dominant-negative MH2 variants is biologically coherent but remains preliminary. (wagenaar2024functionalanalysisof pages 1-3, wagenaar2024functionalanalysisof pages 3-6)

Therapeutically, mouse results nominate macrophage recruitment, iNOS, MMP2/9, and maladaptive inflammation. In the AngII model, macrophage depletion and iNOS inhibition prevented aneurysmal pathology; the abstract concludes that these “represent 2 promising approaches” meriting further investigation. They are not approved AOS therapies, and broad immune or TGF-β inhibition could be harmful because SMAD3 also supports matrix-preserving repair. (pluijm2016defectiveconnectivetissue pages 1-2, tan2013smad3deficiencypromotes pages 1-2)

Evidence table with exact available abstract quotations

The following table distinguishes primary mechanistic and genotype–phenotype evidence from management reviews. “Unavailable” means no abstract text was retrieved; no quotation has been reconstructed from secondary sources.

Study/year Design/domain Key quantitative or mechanistic result Exact verbatim sentence(s) from the available abstract DOI/URL PMID
van de Laar et al., 2011, Nature Genetics Seminal discovery; human genetics/clinical syndrome definition Discovery study establishing SMAD3 as cause of syndromic aortic aneurysm/dissection with early-onset osteoarthritis; abstract not available in retrieved text. (asta2023geneticbasisnew pages 14-15) Abstract unavailable in retrieved text; do not quote. DOI: 10.1038/ng.744; https://doi.org/10.1038/ng.744 not available in retrieved text
Tan et al., 2013, J Am Heart Assoc Mouse mechanism; inflammation/biomechanics/iNOS-MMP axis States ~90% of patients with distinct SMAD3 mutations develop aneurysm/dissection; in mice, AngII-driven inflammation rather than hypertension caused aneurysm/dissection/rupture; mechanism implicated macrophage iNOS and MMP2/9. (tan2013smad3deficiencypromotes pages 1-2) “Ninety percent of the patients carrying distinct SMAD3 mutations develop aortic aneurysms and dissections, called aneurysms‐osteoarthritis syndrome (AOS).” “We have shown that angiotensin II–induced vascular inflammation, but not hypertension, leads to aortic aneurysms and dissections, ultimately causing aortic rupture and death in mice.” “Chromatin immunoprecipitation (ChIP) and re‐ChIP assays revealed that the underlying mechanism involved aberrant upregulation of inducible nitric oxide synthase (iNOS)–derived nitric oxide production and activation of elastolytic matrix metalloproteinases 2 and 9.” “Administration of clodronate‐liposomes and iNOS inhibitor completely abrogated these aortic conditions, thereby identifying iNOS‐mediated nitric oxide secretion from macrophages as the downstream event of SMAD3 that drives this severe pathology.” DOI: 10.1161/JAHA.113.000269; https://doi.org/10.1161/jaha.113.000269 not available in retrieved text
van der Pluijm et al., 2016, EBioMedicine Mouse mechanism; remodeling/TGF-β paradox/ECM-VSMC biology Smad3 deficiency caused rapid aneurysm growth and premature death; paradoxical increased pSmad2/pERK without downstream transcriptional activation; medial elastin disruption/adventitial inflammation; suggests immune suppression may be more beneficial than targeting TGF-β signaling. (pluijm2016defectiveconnectivetissue pages 1-2, pluijm2016defectiveconnectivetissue pages 9-10) “Aneurysm-osteoarthritis syndrome characterized by unpredictable aortic aneurysm formation, is caused by SMAD3 mutations.” “Smad3−/−animals developed aortic aneurysms rapidly, resulting in premature death.” “Aortic wall immunohistochemistry showed no increase in extracellular matrix and collagen accumulation, nor loss of vascular smooth muscle cells (VSMCs) but instead revealed medial elastin disruption and adventitial inflammation.” “Although Smad3−/−aortas showed increased nuclear pSmad2 and pErk, indicating TGF-β receptor activation, downstream TGF-β-activated target genes were not upregulated.” “Increased pSmad2 and pErk staining in pre-aneurysmal Smad3−/−aortas implied that aortic damage and TGF-β receptor-activated signaling precede aortic inflammation.” “Smad3 deficiency leads to imbalanced activation of downstream genes, no activation of MMPs in VSMCs, and immune responses resulting in rapid aortic wall dilatation and rupture.” DOI: 10.1016/j.ebiom.2016.09.006; https://doi.org/10.1016/j.ebiom.2016.09.006 not available in retrieved text
de Wagenaar et al., 2024, Human Molecular Genetics / preprint text retrieved Human cohort + patient-derived fibroblasts/VSMCs; genotype-phenotype LDS3/AOS phenotype is highly variable; DN MH2 variants trended to more major events and younger first event than haploinsufficient variants; functional differences in differentiation, SMA/MYH11, and ECM formation. (wagenaar2024functionalanalysisof pages 1-3, wagenaar2024functionalanalysisof pages 3-6) “Pathogenic (P) and likely pathogenic (LP) variants in the SMAD3 gene cause Loeys-Dietz syndrome type 3 (LDS3), also known as aneurysms-osteoarthritis syndrome (AOS).” “The phenotype of LDS3 is highly variable and characterized by arterial aneurysms, dissections and tortuosity throughout the vascular system combined with skeletal, cutaneous and facial features.” “Individuals with dominant negative (DN) variants in the MH2 protein interaction domain of SMAD3 exhibited a higher frequency of major events (66.7% vs. 44.0%, p=0.054), occurring at a younger age compared to those with haploinsufficient (HI) variants.” “Moreover, the age at the onset of the first major event was notably younger in individuals with DN variants in MH2, 35.0 years [IQR 29.0-47.0], compared to 46.0 years [IQR 40.0-54.0] in those with HI variants (p=0.065).” “Conversely, DN SMAD3 variant myofibroblasts demonstrated reduced extracellular matrix (ECM) formation compared to control cell lines.” DOI/URL in retrieved text: https://doi.org/10.1101/2023.12.11.571192 not available in retrieved text
Monda et al., 2023, Diagnostics Contemporary management review summarizing LDS/HTAD guidance Review states LDS requires whole-body imaging at diagnosis and 6-month follow-up to assess enlargement; recommends beta-blockers and/or ARBs from diagnosis; individualized surgery thresholds; TEVAR generally not recommended. (monda2023theroleof pages 6-7) “Thus, the 2022 ACC/AHA guidelines for aortic diseases recommend whole body imaging (from cerebral circulation to pelvis) in all patients with LDS at diagnosis and six monthly afterwards to establish if enlargement is occurring [5].” “Currently, 2022 ACC/AHA guidelines for aortic disease recommend starting beta-blockers and/or ARBs at the time of diagnosis in order to reduce aortic growth rate and reduce the occurrence of aortic events [5].” “Thus, according to the 2022 ACC/AHA guidelines, the thresholds for aortic surgery should be individualized according to the type of mutations and presence of additional risk factors [5].” “Endovascular aneurysm repair (TEVAR) is not recommended in these patients because progressive aneurysm development may generate a false lumen and result in graft failure.” DOI: 10.3390/diagnostics13040772; https://doi.org/10.3390/diagnostics13040772 not available in retrieved text
Spaziani et al., 2024, Diagnostics Contemporary management review; pregnancy/exercise in HTAD Review summarizes pregnancy counseling, imaging, BP control, avoidance of ARBs in pregnancy, and avoidance of power sports in HTAD including LDS-risk contexts. (spaziani2024hereditarythoracicaortic pages 12-13, spaziani2024hereditarythoracicaortic pages 13-15) “All women with HTAD should undergo pre-conceptional counselling from adolescence about the risks of aortic dissection related to pregnancy, and appropriate aortic imaging with transthoracic echocardiography, cardiac magnetic resonance or computed tomography is recommended [5].” “Strict control of blood pressure is advised to prevent values exceeding 130/80 mmHg. BBs are the drug of choice for the treatment of systemic hypertension, while ARBs are contraindicated in pregnancy due to fetal toxicity [64].” “Generally, power exercises are not recommended, while skill sports with a lower impact on blood pressure are preferred [75].” DOI: 10.3390/diagnostics14010112; https://doi.org/10.3390/diagnostics14010112 not available in retrieved text
Asta et al., 2023, Int J Environ Res Public Health Contemporary management review; medical therapy/prognosis in syndromic aortopathies Review states β-blockers and sartans remain first-line; losartan reduces SMAD2 phosphorylation/ERK signaling; prognosis improved with earlier diagnosis/follow-up. (asta2023geneticbasisnew pages 12-14) “According to the latest American guidelines, β-blockers and sartans continue to be the drugs of first choice in the treatment of SADs [28].” “Losartan, an angiotensin II receptor antagonist, reduces the phosphorylation of SMAD2 and inhibits the ERK-2 kinase pathway, resulting in a negative regulation of TGF-β [59].” “The life expectancy of patients affected by SADs has certainly undergone a significant improvement in the last 20 years thanks to ever earlier genetic diagnoses, more defined follow-up programs, and therefore the possibility of performing elective surgery.” DOI: 10.3390/ijerph20166615; https://doi.org/10.3390/ijerph20166615 not available in retrieved text

Table: This table compiles pivotal discovery, mechanistic, genotype-phenotype, and management sources for SMAD3-related aneurysm-osteoarthritis syndrome using only quotations and identifiers available in retrieved text. It is designed to support a fully cited final report while clearly separating primary evidence from contemporary review guidance.

Key primary and authoritative references

  1. van de Laar IMBH et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nature Genetics. February 2011;43:121–126. PMID 21217753. DOI: 10.1038/ng.744. (asta2023geneticbasisnew pages 14-15)
  2. van der Linde D et al. Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. Journal of the American College of Cardiology. July 2012;60:397–403. DOI: 10.1016/j.jacc.2011.12.052.
  3. van de Laar IMBH et al. Phenotypic spectrum of the SMAD3-related aneurysms–osteoarthritis syndrome. Journal of Medical Genetics. January 2012;49:47–57. DOI: 10.1136/jmedgenet-2011-100382.
  4. van der Linde D et al. Aneurysm-osteoarthritis syndrome with visceral and iliac artery aneurysms. Journal of Vascular Surgery. January 2013;57:96–102. DOI: 10.1016/j.jvs.2012.06.107.
  5. Tan CK et al. SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II–infused mice via activation of iNOS. Journal of the American Heart Association. June 2013;2:e000269. DOI: 10.1161/JAHA.113.000269. (tan2013smad3deficiencypromotes pages 1-2)
  6. van der Pluijm I et al. Defective connective tissue remodeling in Smad3 mice leads to accelerated aneurysmal growth through disturbed downstream TGF-β signaling. EBioMedicine. October 2016;12:280–294. DOI: 10.1016/j.ebiom.2016.09.006. (pluijm2016defectiveconnectivetissue pages 9-10, pluijm2016defectiveconnectivetissue pages 1-2)
  7. de Wagenaar NP et al. Functional analysis of cell lines derived from SMAD3-related Loeys-Dietz syndrome patients provides insights into genotype-phenotype relation. Human Molecular Genetics. 2024;33:1090–1104. Retrieved preprint DOI: 10.1101/2023.12.11.571192, posted December 12, 2023. (wagenaar2024functionalanalysisof pages 1-3)
  8. Isselbacher EM et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. November 2022;146:e334–e482/e483. PMID 36322642. DOI: 10.1161/CIR.0000000000001106. Contemporary reviews applying this guidance are available at Monda et al. 2023 and Spaziani et al. 2024. (monda2023theroleof pages 6-7, spaziani2024hereditarythoracicaortic pages 12-13)

Bottom line

SMAD3-related AOS is best understood as a failure of TGF-β/SMAD3-dependent connective-tissue homeostasis affecting both arterial media and synovial/osteochondral tissues. The apparent increase in aortic-wall TGF-β markers is a compensatory and compartment-specific phenomenon occurring alongside defective SMAD3 transcription—not evidence of simple pathway overactivity. Because vascular disease is systemic, variably penetrant, and capable of dissecting at relatively small diameters, molecular diagnosis must trigger lifelong head-to-pelvis surveillance, family testing, early hemodynamic therapy, individualized low-threshold surgery, and avoidance of major blood-pressure stress.

References

  1. (pluijm2016defectiveconnectivetissue pages 9-10): I. van der Pluijm, N. van Vliet, J.H. von der Thusen, J.L. Robertus, Y. Ridwan, P.M. van Heijningen, B.S. van Thiel, M. Vermeij, S.E. Hoeks, R.M.G.B. Buijs-Offerman, H.J.M. Verhagen, R. Kanaar, A.M. Bertoli-Avella, and J. Essers. Defective connective tissue remodeling in smad3 mice leads to accelerated aneurysmal growth through disturbed downstream tgf-β signaling. EBioMedicine, 12:280-294, Oct 2016. URL: https://doi.org/10.1016/j.ebiom.2016.09.006, doi:10.1016/j.ebiom.2016.09.006. This article has 51 citations and is from a peer-reviewed journal.

  2. (pluijm2016defectiveconnectivetissue pages 1-2): I. van der Pluijm, N. van Vliet, J.H. von der Thusen, J.L. Robertus, Y. Ridwan, P.M. van Heijningen, B.S. van Thiel, M. Vermeij, S.E. Hoeks, R.M.G.B. Buijs-Offerman, H.J.M. Verhagen, R. Kanaar, A.M. Bertoli-Avella, and J. Essers. Defective connective tissue remodeling in smad3 mice leads to accelerated aneurysmal growth through disturbed downstream tgf-β signaling. EBioMedicine, 12:280-294, Oct 2016. URL: https://doi.org/10.1016/j.ebiom.2016.09.006, doi:10.1016/j.ebiom.2016.09.006. This article has 51 citations and is from a peer-reviewed journal.

  3. (wagenaar2024functionalanalysisof pages 1-3): Nathalie P. de Wagenaar, Lisa M. van den Bersselaar, Hanny J.H.M. Odijk, Sanne J.M. Stefens, Dieter P. Reinhardt, Jolien W. Roos-Hesselink, Roland Kanaar, Judith M.A. Verhagen, Hennie T. Brüggenwirth, Ingrid M.B.H. van de Laar, Ingrid van der Pluijm, and Jeroen Essers. Functional analysis of cell lines derived from smad3-related loeys-dietz syndrome patients provides insights into genotype-phenotype relation. Human Molecular Genetics, 33:1090-1104, Dec 2024. URL: https://doi.org/10.1101/2023.12.11.571192, doi:10.1101/2023.12.11.571192. This article has 4 citations and is from a domain leading peer-reviewed journal.

  4. (wagenaar2024functionalanalysisof pages 3-6): Nathalie P. de Wagenaar, Lisa M. van den Bersselaar, Hanny J.H.M. Odijk, Sanne J.M. Stefens, Dieter P. Reinhardt, Jolien W. Roos-Hesselink, Roland Kanaar, Judith M.A. Verhagen, Hennie T. Brüggenwirth, Ingrid M.B.H. van de Laar, Ingrid van der Pluijm, and Jeroen Essers. Functional analysis of cell lines derived from smad3-related loeys-dietz syndrome patients provides insights into genotype-phenotype relation. Human Molecular Genetics, 33:1090-1104, Dec 2024. URL: https://doi.org/10.1101/2023.12.11.571192, doi:10.1101/2023.12.11.571192. This article has 4 citations and is from a domain leading peer-reviewed journal.

  5. (tan2013smad3deficiencypromotes pages 1-2): Chek K. Tan, Eddie H. Tan, Baiwen Luo, Charlotte L. Huang, Joachim S. Loo, Cleo Choong, and Nguan S. Tan. Smad3 deficiency promotes inflammatory aortic aneurysms in angiotensin ii–infused mice via activation of inos. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Jun 2013. URL: https://doi.org/10.1161/jaha.113.000269, doi:10.1161/jaha.113.000269. This article has 71 citations and is from a domain leading peer-reviewed journal.

  6. (asta2023geneticbasisnew pages 14-15): Laura Asta, Gianluca A. D’Angelo, Daniele Marinelli, and Umberto Benedetto. Genetic basis, new diagnostic approaches, and updated therapeutic strategies of the syndromic aortic diseases: marfan, loeys–dietz, and vascular ehlers–danlos syndrome. International Journal of Environmental Research and Public Health, 20(16):6615, Aug 2023. URL: https://doi.org/10.3390/ijerph20166615, doi:10.3390/ijerph20166615. This article has 41 citations.

  7. (monda2023theroleof pages 6-7): Emanuele Monda, Michele Lioncino, Federica Verrillo, Marta Rubino, Martina Caiazza, Alfredo Mauriello, Natale Guarnaccia, Adelaide Fusco, Annapaola Cirillo, Simona Covino, Ippolita Altobelli, Gaetano Diana, Giuseppe Palmiero, Francesca Dongiglio, Francesco Natale, Arturo Cesaro, Eduardo Bossone, Maria Giovanna Russo, Paolo Calabrò, and Giuseppe Limongelli. The role of genetic testing in patients with heritable thoracic aortic diseases. Diagnostics, 13:772, Feb 2023. URL: https://doi.org/10.3390/diagnostics13040772, doi:10.3390/diagnostics13040772. This article has 23 citations.

  8. (asta2023geneticbasisnew pages 12-14): Laura Asta, Gianluca A. D’Angelo, Daniele Marinelli, and Umberto Benedetto. Genetic basis, new diagnostic approaches, and updated therapeutic strategies of the syndromic aortic diseases: marfan, loeys–dietz, and vascular ehlers–danlos syndrome. International Journal of Environmental Research and Public Health, 20(16):6615, Aug 2023. URL: https://doi.org/10.3390/ijerph20166615, doi:10.3390/ijerph20166615. This article has 41 citations.

  9. (spaziani2024hereditarythoracicaortic pages 12-13): Gaia Spaziani, Francesca Chiara Surace, Francesca Girolami, Francesco Bianco, Valentina Bucciarelli, Francesca Bonanni, Elena Bennati, Luigi Arcieri, and Silvia Favilli. Hereditary thoracic aortic diseases. Diagnostics, 14:112, Jan 2024. URL: https://doi.org/10.3390/diagnostics14010112, doi:10.3390/diagnostics14010112. This article has 5 citations.

  10. (spaziani2024hereditarythoracicaortic pages 13-15): Gaia Spaziani, Francesca Chiara Surace, Francesca Girolami, Francesco Bianco, Valentina Bucciarelli, Francesca Bonanni, Elena Bennati, Luigi Arcieri, and Silvia Favilli. Hereditary thoracic aortic diseases. Diagnostics, 14:112, Jan 2024. URL: https://doi.org/10.3390/diagnostics14010112, doi:10.3390/diagnostics14010112. This article has 5 citations.

Artifacts